Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference newsletter


  Ovarian Neoplasms

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 761 articles:
HTML format



Single Articles


    October 2020
  1. CEPPI L, Grassi T, Galli F, Buda A, et al
    Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)34036.
    PubMed     Abstract available


  2. BARBER EL, Garg R, Persenaire C, Simon M, et al
    Natural language processing with machine learning to predict outcomes after ovarian cancer surgery.
    Gynecol Oncol. 2020 Oct 14. pii: S0090-8258(20)34012.
    PubMed     Abstract available


  3. MORTON M, Chambers LM, Costales AB, Chichura A, et al
    Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 13. pii: S0090-8258(20)33962.
    PubMed     Abstract available


  4. MICHELS J, Genestie C, Dunant A, Caron O, et al
    Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
    Gynecol Oncol. 2020 Oct 12. pii: S0090-8258(20)33960.
    PubMed     Abstract available


  5. HAUNSCHILD CE, Tewari KS
    The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 11. pii: S0090-8258(20)33953.
    PubMed     Abstract available


  6. NICA A, Lee JYJ, Hong NL, May T, et al
    Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 6. pii: S0090-8258(20)33961.
    PubMed     Abstract available


  7. CORVIGNO S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, et al
    High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33951.
    PubMed     Abstract available


  8. UBACHS J, Koole SN, Lahaye M, Fabris C, et al
    No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33952.
    PubMed     Abstract available


  9. LENTZ SE, Powell CB, Haque R, Armstrong MA, et al
    Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
    Gynecol Oncol. 2020 Oct 1. pii: S0090-8258(20)33914.
    PubMed     Abstract available


    September 2020
  10. KOTSOPOULOS J, Gronwald J, McCuaig JM, Karlan BY, et al
    Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2020 Sep 30. pii: S0090-8258(20)33947.
    PubMed     Abstract available


  11. CHAN JK, Liang SY, Kapp DS, Chan JE, et al
    Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33910.
    PubMed    


  12. MIRZA MR, Benigno B, Dorum A, Mahner S, et al
    Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33899.
    PubMed     Abstract available


  13. WICHMANN C, Klotz DM, Zeiler HJ, Hilger RA, et al
    The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33911.
    PubMed     Abstract available


  14. MANRRIQUEZ E, Mandelbaum A, Aguayo E, Zakhour M, et al
    Factors associated with high-cost hospitalizations in elderly ovarian cancer patients.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33919.
    PubMed     Abstract available


  15. CHARO LM, Jou J, Binder P, Hohmann SF, et al
    Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33915.
    PubMed     Abstract available


  16. EAKIN CM, Norton TJ, Monk BJ, Chase DM, et al
    Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33817.
    PubMed     Abstract available


  17. MUSORO JZ, Coens C, Greimel E, King MT, et al
    Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33900.
    PubMed     Abstract available


  18. BANTIE L, Tadesse S, Likisa J, Yu M, et al
    A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33905.
    PubMed     Abstract available


  19. GUNAY G, Kirit HA, Kamatar A, Baghdasaryan O, et al
    The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33857.
    PubMed     Abstract available


  20. MUSTON D, Hettle R, Monberg M, McLaurin KK, et al
    Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33814.
    PubMed     Abstract available


  21. KANBERGS AN, Manning-Geist BL, Pelletier A, Sullivan MW, et al
    Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33904.
    PubMed     Abstract available


  22. JORDAN SE, Saad H, Covarrubias AS, Siemon J, et al
    mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population.
    Gynecol Oncol. 2020 Sep 17. pii: S0090-8258(20)33831.
    PubMed     Abstract available


  23. CHAMBERS LM, Kuznicki M, Yao M, Chichura A, et al
    Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Sep 16. pii: S0090-8258(20)33903.
    PubMed     Abstract available


  24. PALMQVIST C, Staf C, Mateoiu C, Johansson M, et al
    Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment.
    Gynecol Oncol. 2020 Sep 15. pii: S0090-8258(20)33897.
    PubMed     Abstract available


  25. HURWITZ LM, Pinsky PF, Huang WY, Freedman ND, et al
    Aspirin use and ovarian cancer risk using extended follow-up of the PLCO Cancer Screening Trial.
    Gynecol Oncol. 2020 Sep 10. pii: S0090-8258(20)33855.
    PubMed     Abstract available


  26. PLETT H, Filippova OT, Garbi A, Kommoss S, et al
    Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study.
    Gynecol Oncol. 2020 Sep 9. pii: S0090-8258(20)33829.
    PubMed     Abstract available


  27. MADARIAGA A, Garg S, Bruce JP, Thiryayi S, et al
    Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer.
    Gynecol Oncol. 2020 Sep 7. pii: S0090-8258(20)33849.
    PubMed     Abstract available


    August 2020
  28. SIA TY, Wen T, Cham S, Friedman AM, et al
    Effect of frailty on postoperative readmissions and cost of care for ovarian cancer.
    Gynecol Oncol. 2020 Aug 28. pii: S0090-8258(20)33825.
    PubMed     Abstract available


  29. GONZALEZ R, Havrilesky LJ, Myers ER, Secord AA, et al
    Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
    Gynecol Oncol. 2020 Aug 27. pii: S0090-8258(20)33759.
    PubMed     Abstract available


  30. RICHARDSON MT, Mysona DP, Klein DA, Mann A, et al
    Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit.
    Gynecol Oncol. 2020 Aug 20. pii: S0090-8258(20)32386.
    PubMed     Abstract available


  31. AVIKI EM, Lavery JA, Roche KL, Cowan R, et al
    Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer.
    Gynecol Oncol. 2020 Aug 16. pii: S0090-8258(20)33754.
    PubMed     Abstract available


  32. POTHURI B, O'Cearbhaill R, Eskander R, Armstrong D, et al
    Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
    Gynecol Oncol. 2020 Aug 7. pii: S0090-8258(20)33747.
    PubMed     Abstract available


  33. POWELL CB, Laurent C, Ciaravino G, Garcia C, et al
    Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
    Gynecol Oncol. 2020 Aug 7. pii: S0090-8258(20)33662.
    PubMed     Abstract available


  34. BEESLEY VL, Webber K, Nagle CM, DeFazio A, et al
    When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer.
    Gynecol Oncol. 2020 Aug 6. pii: S0090-8258(20)33664.
    PubMed     Abstract available


  35. LEE EK, Xiong N, Cheng SC, Barry WT, et al
    Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
    Gynecol Oncol. 2020 Aug 5. pii: S0090-8258(20)33663.
    PubMed     Abstract available


    July 2020
  36. LEE JM, Annunziata CM, Hays JL, Cao L, et al
    Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
    Gynecol Oncol. 2020 Jul 31. pii: S0090-8258(20)33677.
    PubMed     Abstract available


  37. TEWARI KS, Sill MW, Coleman RL, Aghajanian C, et al
    Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)32390.
    PubMed     Abstract available


  38. SCHWARTZ GG, Tretli S, Klug MG, Robsahm TE, et al
    Women who develop ovarian cancer show an increase in serum calcium and a decrease in serum albumin. A longitudinal study in the Janus Serum Bank Cohort.
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)32381.
    PubMed     Abstract available


  39. ROBELIN P, Tod M, Colomban O, Lachuer J, et al
    Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)33656.
    PubMed     Abstract available


  40. FALCONER H, Joneborg U, Krawiec K, Palsdottir K, et al
    Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32384.
    PubMed     Abstract available


  41. ANGELES MA, Rychlik A, Cabarrou B, Spagnolo E, et al
    A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32321.
    PubMed     Abstract available


  42. LORUSSO D, Marchetti C, Conte C, Giudice E, et al
    Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study.
    Gynecol Oncol. 2020 Jul 20. pii: S0090-8258(20)33657.
    PubMed     Abstract available


  43. TAYLAN E, Zayou F, Murali R, Karlan BY, et al
    Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model.
    Gynecol Oncol. 2020 Jul 19. pii: S0090-8258(20)32380.
    PubMed     Abstract available


  44. WU JL, Zhao J, Zhang HB, Zuo WW, et al
    Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)32387.
    PubMed     Abstract available


  45. ZHENG L, Cui C, Shi O, Lu X, et al
    Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990-2017.
    Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)32383.
    PubMed     Abstract available


  46. ROSS TL, DeFazio A, Friedlander M, Grant P, et al
    Insomnia and its association with quality of life in women with ovarian cancer.
    Gynecol Oncol. 2020 Jul 9. pii: S0090-8258(20)32326.
    PubMed     Abstract available


  47. BRIEGER KK, Peterson S, Lee AW, Mukherjee B, et al
    Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.
    Gynecol Oncol. 2020 Jul 5. pii: S0090-8258(20)32296.
    PubMed     Abstract available


    June 2020
  48. JONES TL, Sandler CX, Spence RR, Hayes SC, et al
    Physical activity and exercise in women with ovarian cancer: A systematic review.
    Gynecol Oncol. 2020 Jun 29. pii: S0090-8258(20)32300.
    PubMed     Abstract available


  49. LAGO V, Fotopoulou C, Chiantera V, Minig L, et al
    Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction.
    Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)31132.
    PubMed     Abstract available


  50. DILLEY J, Burnell M, Gentry-Maharaj A, Ryan A, et al
    Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)31029.
    PubMed     Abstract available


  51. NICA A, Covens A, Parra-Herran C, May T, et al
    Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
    Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)32293.
    PubMed     Abstract available


  52. MARCHETTI C, Minucci A, D'Indinosante M, Ergasti R, et al
    Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.
    Gynecol Oncol. 2020 Jun 15. pii: S0090-8258(20)32294.
    PubMed     Abstract available


  53. MOORE KN, Birrer MJ, Marsters J, Wang Y, et al
    Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2020 Jun 11. pii: S0090-8258(20)31124.
    PubMed     Abstract available


  54. NARASIMHULU DM, McGree ME, Weaver AL, Jatoi A, et al
    Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31131.
    PubMed     Abstract available


  55. BOGANI G, Lopez S, Mantiero M, Ducceschi M, et al
    Immunotherapy for platinum-resistant ovarian cancer.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31924.
    PubMed     Abstract available


  56. STRAUBHAR AM, Filippova OT, Cowan RA, Lakhman Y, et al
    A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31126.
    PubMed     Abstract available


  57. HAMILTON E, O'Malley DM, O'Cearbhaill R, Cristea M, et al
    Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
    Gynecol Oncol. 2020 Jun 5. pii: S0090-8258(20)31123.
    PubMed     Abstract available


  58. ARMEL SR, Volenik A, Demsky R, Malcolmson J, et al
    Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing.
    Gynecol Oncol. 2020 Jun 3. pii: S0090-8258(20)31082.
    PubMed     Abstract available


  59. BOLAND JL, Zhou Q, Iasonos AE, O'Cearbhaill RE, et al
    Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy.
    Gynecol Oncol. 2020 Jun 2. pii: S0090-8258(20)31073.
    PubMed     Abstract available


  60. ROCHE KL, Chi DS
    Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward...or too much risk?
    Gynecol Oncol. 2020;157:561-562.
    PubMed    


  61. CHAMBERS LM, Pendlebury A, Rose PG, Yao M, et al
    Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2020 Jun 1. pii: S0090-8258(20)31018.
    PubMed     Abstract available


    May 2020
  62. KNISELY A, Huang Y, Melamed A, Tergas AI, et al
    Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes.
    Gynecol Oncol. 2020 May 23. pii: S0090-8258(20)31085.
    PubMed     Abstract available


  63. GLEESON M, Kentwell M, Meiser B, Do J, et al
    The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.
    Gynecol Oncol. 2020 May 22. pii: S0090-8258(20)31028.
    PubMed     Abstract available


  64. MATSUO K, Chang EJ, Matsuzaki S, Mandelbaum RS, et al
    Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes.
    Gynecol Oncol. 2020 May 10. pii: S0090-8258(20)30304.
    PubMed     Abstract available


  65. LUO S, Zhang Y, Yang Y, Zhu S, et al
    Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy.
    Gynecol Oncol. 2020 May 8. pii: S0090-8258(20)30995.
    PubMed     Abstract available


  66. BOUCHARD-FORTIER G, Cusimano MC, Fazelzad R, Sajewycz K, et al
    Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 May 6. pii: S0090-8258(20)30259.
    PubMed     Abstract available


  67. SIVAKUMARAN T, Mileshkin L, Grant P, Na L, et al
    Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
    Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)31016.
    PubMed     Abstract available


  68. SONG F, Li L, Zhang B, Zhao Y, et al
    Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
    Gynecol Oncol. 2020 May 1. pii: S0090-8258(20)30988.
    PubMed     Abstract available


    April 2020
  69. STAPLES JN, Peres LC, Camacho F, Alberg AJ, et al
    Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES).
    Gynecol Oncol. 2020 Apr 30. pii: S0090-8258(20)31010.
    PubMed     Abstract available


  70. MONK BJ, Coleman RL, Moore KN, Herzog TJ, et al
    COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies.
    Gynecol Oncol. 2020 Apr 29. pii: S0090-8258(20)31013.
    PubMed    


  71. CHEN Y, Li G
    Gynecological malignancies with asymptomatic SARS-CoV-2 infection during the convalescence of outbreak.
    Gynecol Oncol. 2020 Apr 29. pii: S0090-8258(20)31019.
    PubMed    


  72. SEARLE G, Pounds R, Phillips A, Kehoe S, et al
    Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis.
    Gynecol Oncol. 2020 Apr 25. pii: S0090-8258(20)30307.
    PubMed     Abstract available


  73. MAJIDI A, Na R, Dixon-Suen S, Jordan SJ, et al
    Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Apr 18. pii: S0090-8258(20)30253.
    PubMed     Abstract available


  74. HOOGSTAD-VAN EVERT JS, Bekkers R, Ottevanger N, Jansen JH, et al
    Harnessing natural killer cells for the treatment of ovarian cancer.
    Gynecol Oncol. 2020 Apr 5. pii: S0090-8258(20)30236.
    PubMed     Abstract available


  75. AREND RC, Beer HM, Cohen YC, Berlin S, et al
    Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
    Gynecol Oncol. 2020 Apr 5. pii: S0090-8258(20)30180.
    PubMed     Abstract available


  76. NARASIMHULU DM, Kumar A, Weaver AL, Langstraat CL, et al
    Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management.
    Gynecol Oncol. 2020 Apr 1. pii: S0090-8258(20)30249.
    PubMed     Abstract available


  77. CHEVROT A, Pouget N, Bats AS, Huchon C, et al
    Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group.
    Gynecol Oncol. 2020;157:29-35.
    PubMed     Abstract available


  78. SCOTT SA, Llaurado Fernandez M, Kim H, Elit L, et al
    Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
    Gynecol Oncol. 2020;157:36-45.
    PubMed     Abstract available


    March 2020
  79. BENNETSEN AKK, Baandrup L, Aalborg GL, Kjaer SK, et al
    Non-epithelial ovarian cancer in Denmark - Incidence and survival over nearly 40years.
    Gynecol Oncol. 2020 Mar 26. pii: S0090-8258(20)30246.
    PubMed     Abstract available


  80. GONZALEZ R, Gockley AA, Melamed A, Sugrue R, et al
    Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer.
    Gynecol Oncol. 2020 Mar 25. pii: S0090-8258(20)30228.
    PubMed     Abstract available


  81. BETELLA I, Turbitt WJ, Szul T, Wu B, et al
    Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.
    Gynecol Oncol. 2020 Mar 16. pii: S0090-8258(20)30226.
    PubMed     Abstract available


  82. LIONTOS M, Sotiropoulou M, Kaparelou M, Tzannis K, et al
    Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.
    Gynecol Oncol. 2020 Mar 12. pii: S0090-8258(20)30224.
    PubMed     Abstract available


  83. ROZE JF, Veldhuis WB, Hoogendam JP, Verheijen RHM, et al
    Prognostic value of radiological recurrence patterns in ovarian cancer.
    Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30219.
    PubMed     Abstract available


  84. VAN WALREE IC, Bretveld R, van Huis-Tanja LH, Louwers JA, et al
    Reasons for guideline non-adherence in older and younger women with advanced stage ovarian cancer.
    Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30221.
    PubMed     Abstract available


  85. LEVY T, Migdan Z, Aleohin N, Ben-Shem, et al
    Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome.
    Gynecol Oncol. 2020 Mar 6. pii: S0090-8258(20)30158.
    PubMed     Abstract available


  86. HAQUE R, Skates SJ, Armstrong MA, Lentz SE, et al
    Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations.
    Gynecol Oncol. 2020 Mar 4. pii: S0090-8258(20)30164.
    PubMed     Abstract available


  87. PIERSON WE, Peters PN, Chang MT, Chen LM, et al
    An integrated molecular profile of endometrioid ovarian cancer.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30144.
    PubMed     Abstract available


  88. GONTHIER C, Douhnai D, Koskas M
    Lymph node metastasis probability in young patients eligible for conservative management of endometrial cancer.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30157.
    PubMed     Abstract available


  89. MOORE KN, Zorn KK
    Germline and Somatic Testing in Ovarian Cancer: Shifting Sands of Recommendations.
    Gynecol Oncol. 2020;156:515-516.
    PubMed    


  90. POWELL CB, Littell RD, Landen CN Jr, Pramanik S, et al
    Cytological sampling of fallopian tubes using a hysteroscopic catheter: A multi-center study.
    Gynecol Oncol. 2020;156:636-640.
    PubMed     Abstract available


  91. LENCK C, Chopin N, Gouy S, Bonsang-Kitzis H, et al
    The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.
    Gynecol Oncol. 2020 Mar 1. pii: S0090-8258(20)30145.
    PubMed     Abstract available


    February 2020
  92. CHANG CP, Chen Y, Blackburn B, Abdelaziz S, et al
    Genitourinary disease risks among ovarian cancer survivors in a population-based cohort study.
    Gynecol Oncol. 2020 Feb 28. pii: S0090-8258(20)30162.
    PubMed     Abstract available


  93. O'MALLEY DM, Matulonis UA, Birrer MJ, Castro CM, et al
    Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2020 Feb 18. pii: S0090-8258(20)30090.
    PubMed     Abstract available


  94. FREY MK, Lee SS, Gerber D, Schwartz ZP, et al
    Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.
    Gynecol Oncol. 2020 Feb 11. pii: S0090-8258(20)30007.
    PubMed     Abstract available


  95. PETERSEN S, Wilson AJ, Hirst J, Roby KF, et al
    CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
    Gynecol Oncol. 2020 Feb 7. pii: S0090-8258(20)30091.
    PubMed     Abstract available


  96. PIAO J, Lee EJ, Lee M
    Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30097.
    PubMed     Abstract available


  97. ROJAS C, Tian C, Powell MA, Chan JK, et al
    Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
    Gynecol Oncol. 2020 Feb 3. pii: S0090-8258(20)30057.
    PubMed     Abstract available


  98. SOLSKY I, Chen J, Rebbeck TR
    Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
    Gynecol Oncol. 2020;156:363-376.
    PubMed     Abstract available


  99. DOGAN NU, Dogan S, Erol M, Uzun BT, et al
    Cisterna chyli: An important landmark in laparoscopic paraaortic lymphadenectomy.
    Gynecol Oncol. 2020;156:511.
    PubMed     Abstract available


  100. VENERIS JT, Matulonis UA, Liu JF, Konstantinopoulos PA, et al
    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
    Gynecol Oncol. 2020;156:488-497.
    PubMed     Abstract available


    January 2020
  101. KORENAGA TR, Ward KK, Saenz C, McHale MT, et al
    The elevated risk of ovarian clear cell carcinoma among Asian Pacific Islander women in the United States is not affected by birthplace.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30086.
    PubMed     Abstract available


  102. SIEMON J, Galli J, Slomovitz B, Schlumbrecht M, et al
    Disparities in care among patients with low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(19)31871.
    PubMed     Abstract available


  103. NASIOUDIS D, Mastroyannis SA, Latif NA, Ko EM, et al
    Trends in the surgical management of malignant ovarian germ-cell tumors.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30087.
    PubMed     Abstract available


  104. CABASAG CJ, Butler J, Arnold M, Rutherford M, et al
    Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study.
    Gynecol Oncol. 2020 Jan 28. pii: S0090-8258(19)31877.
    PubMed     Abstract available


  105. XUE C, Xu Y, Ye W, Xie Q, et al
    Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
    Gynecol Oncol. 2020 Jan 24. pii: S0090-8258(19)31804.
    PubMed     Abstract available


  106. STEWART LM, Stewart CJR, Spilsbury K, Cohen PA, et al
    Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma.
    Gynecol Oncol. 2020 Jan 23. pii: S0090-8258(20)30080.
    PubMed     Abstract available


  107. HAVRILESKY LJ, Lim S, Ehrisman JA, Lorenzo A, et al
    Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
    Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30070.
    PubMed     Abstract available


  108. BOGANI G, Ditto A, Lopez S, Bertolina F, et al
    Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Jan 21. pii: S0090-8258(19)31875.
    PubMed     Abstract available


  109. SLOMOVITZ B, Gourley C, Carey MS, Malpica A, et al
    Low-grade serous ovarian cancer: State of the science.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(19)31862.
    PubMed     Abstract available


  110. FEKETE JT, Osz A, Pete I, Nagy GR, et al
    Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(20)30006.
    PubMed     Abstract available


  111. CADOO KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, et al
    A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
    Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30060.
    PubMed     Abstract available


  112. NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
    Primary malignant ovarian carcinoid; management and outcomes.
    Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30002.
    PubMed     Abstract available


  113. ACOSTA-TORRES S, Fader AN
    Laparoscopic splenectomy for secondary cytoreduction of ovarian cancer in a woman with localized splenic recurrence.
    Gynecol Oncol. 2020 Jan 16. pii: S0090-8258(19)31842.
    PubMed     Abstract available


  114. MERIDETH MA, Harney LA, Vyas N, Bachi A, et al
    Gynecologic and reproductive health in patients with pathogenic germline variants in DICER1.
    Gynecol Oncol. 2020 Jan 15. pii: S0090-8258(19)31867.
    PubMed     Abstract available


  115. GHIRARDI V, Moruzzi MC, Bizzarri N, Vargiu V, et al
    Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(20)30017.
    PubMed     Abstract available


  116. LLAURADO FERNANDEZ M, Dawson A, Kim H, Lam N, et al
    Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(19)31680.
    PubMed     Abstract available


  117. BEAVIS AL, Yen TT, Stone RL, Wethington SL, et al
    Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?
    Gynecol Oncol. 2020 Jan 13. pii: S0090-8258(19)31849.
    PubMed     Abstract available


  118. BIXEL K, Vetter M, Davidson B, Berchuck A, et al
    Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2020 Jan 11. pii: S0090-8258(19)31837.
    PubMed     Abstract available


  119. MORGAN RD, Banerjee S, Hall M, Clamp AR, et al
    Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30005.
    PubMed     Abstract available


  120. STALEY SA, Tucker K, Newton M, Ertel M, et al
    Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30003.
    PubMed     Abstract available


  121. RAFFONE A, Travaglino A, Mascolo M, Carotenuto C, et al
    Histopathological characterization of ProMisE molecular groups of endometrial cancer.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30008.
    PubMed     Abstract available


  122. WANG D, Zhu S, Jia C, Cao D, et al
    Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: A single center experience.
    Gynecol Oncol. 2020 Jan 9. pii: S0090-8258(19)31872.
    PubMed     Abstract available


  123. MONK BJ, Herzog TJ, Wang G, Triantos S, et al
    A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Gynecol Oncol. 2020 Jan 8. pii: S0090-8258(19)31873.
    PubMed     Abstract available


  124. FRAUNE C, Rosebrock J, Simon R, Hube-Magg C, et al
    High homogeneity of MMR deficiency in ovarian cancer.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31861.
    PubMed     Abstract available


  125. SIAMAKPOUR-REIHANI S, Cobb LP, Jiang C, Zhang D, et al
    Differential expression of immune related genes in high-grade ovarian serous carcinoma.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31840.
    PubMed     Abstract available


  126. PEIRETTI M, Candotti G, Fais ML, Ricciardi E, et al
    Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31870.
    PubMed     Abstract available


  127. BREWER M, Angioli R, Scambia G, Lorusso D, et al
    Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.
    Gynecol Oncol. 2020 Jan 6. pii: S0090-8258(19)31845.
    PubMed     Abstract available


  128. GORRINGE KL, Cheasley D, Wakefield MJ, Ryland GL, et al
    Therapeutic options for mucinous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 2. pii: S0090-8258(19)31836.
    PubMed     Abstract available


  129. VARGHESE A, Shih IM
    Not All Peritoneal Implants Are Created Equal.
    Gynecol Oncol. 2020;156:1-2.
    PubMed    


  130. CHODAVADIA PA, Jacobs CD, Wang F, Havrilesky LJ, et al
    Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data.
    Gynecol Oncol. 2020;156:154-161.
    PubMed     Abstract available


  131. MHAWECH-FAUCEGLIA P, Izevbaye I, Spindler T, Wang G, et al
    Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature.
    Gynecol Oncol. 2020;156:6-12.
    PubMed     Abstract available


    December 2019
  132. SALMINEN L, Nadeem N, Jain S, Grenman S, et al
    A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
    Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31846.
    PubMed     Abstract available


  133. JORGE S, McFaddin AS, Doll KM, Pennington KP, et al
    Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
    Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31802.
    PubMed     Abstract available


  134. WAMBECKE A, Ahmad M, Lambert B, Joly F, et al
    The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.
    Gynecol Oncol. 2019 Dec 26. pii: S0090-8258(19)31841.
    PubMed     Abstract available


  135. KAY AH, Venn M, Urban R, Gray HJ, et al
    Postoperative narcotic use in patients with ovarian cancer on an Enhanced Recovery After Surgery (ERAS) pathway.
    Gynecol Oncol. 2019 Dec 24. pii: S0090-8258(19)31839.
    PubMed     Abstract available


  136. JONES NL, Xiu J, Rocconi RP, Herzog TJ, et al
    Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
    Gynecol Oncol. 2019 Dec 24. pii: S0090-8258(19)31694.
    PubMed     Abstract available


  137. CONNOR YD, Miao D, Lin DI, Hayne C, et al
    Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
    Gynecol Oncol. 2019 Dec 21. pii: S0090-8258(19)31618.
    PubMed     Abstract available


  138. AREND RC, Davis AM, Chimiczewski P, O'Malley DM, et al
    EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low g
    Gynecol Oncol. 2019 Dec 20. pii: S0090-8258(19)31786.
    PubMed     Abstract available


  139. MATSUO K, Machida H, Matsuzaki S, Grubbs BH, et al
    Evolving population-based statistics for rare epithelial ovarian cancers.
    Gynecol Oncol. 2019 Dec 18. pii: S0090-8258(19)31781.
    PubMed     Abstract available


  140. NAUMANN RW, Coleman RL, Brown J, Moore KN, et al
    Corrigendum to "Phase III trials in ovarian cancer: The evolving landscape of front line therapy" [Gynecol. Oncol. 153 (2019) 436-444].
    Gynecol Oncol. 2019 Dec 16. pii: S0090-8258(19)31799.
    PubMed    


  141. KRILL L, Deng W, Eskander R, Mutch D, et al
    Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31795.
    PubMed     Abstract available


  142. NASIOUDIS D, Latif NA, Simpkins F, Cory L, et al
    Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base.
    Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31784.
    PubMed     Abstract available


  143. ZHANG H, Wu X, Xu Z, Sun Z, et al
    Impact of perioperative red blood cell transfusion on postoperative recovery and long-term outcome in patients undergoing surgery for ovarian cancer: A propensity score-matched analysis.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31798.
    PubMed     Abstract available


  144. PERES LC, Sinha S, Townsend MK, Fridley BL, et al
    Predictors of survival trajectories among women with epithelial ovarian cancer.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31803.
    PubMed     Abstract available


  145. ZHANG W, Tan C, Xu M, Wu X, et al
    Primary appendiceal mucinous neoplasm: Gynecological manifestations, management, and prognosis.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31681.
    PubMed     Abstract available


  146. KRIMMEL-MORRISON JD, Ghezelayagh TS, Lian S, Zhang Y, et al
    Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31783.
    PubMed     Abstract available


  147. RONCOLATO FT, O'Connell RL, Joly F, Lanceley A, et al
    Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(>/=3) chemotherapy - The GCIG symptom
    Gynecol Oncol. 2019 Dec 10. pii: S0090-8258(19)31558.
    PubMed     Abstract available


  148. VERGOTE I, Bergfeldt K, Franquet A, Lisyanskaya AS, et al
    A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.
    Gynecol Oncol. 2019 Dec 9. pii: S0090-8258(19)31685.
    PubMed     Abstract available


  149. GITTO SB, Kim H, Rafail S, Omran DK, et al
    An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
    Gynecol Oncol. 2019 Dec 6. pii: S0090-8258(19)31568.
    PubMed     Abstract available


  150. FORSSE D, Tangen IL, Fasmer KE, Halle MK, et al
    Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling.
    Gynecol Oncol. 2019 Dec 5. pii: S0090-8258(19)31782.
    PubMed     Abstract available


  151. HINCHCLIFF E, Jazaeri AA
    Sunset, or dawn of a new age for ovarian cancer vaccine therapy?
    Gynecol Oncol. 2019;155:387-388.
    PubMed    


    November 2019
  152. VERGOTE I, Heitz F, Buderath P, Powell M, et al
    A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2019 Nov 29. pii: S0090-8258(19)31627.
    PubMed     Abstract available


  153. TAKAYA H, Nakai H, Sakai K, Nishio K, et al
    Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31664.
    PubMed     Abstract available


  154. NARASIMHULU DM, Bews KA, Hanson KT, Chang YH, et al
    Using evidence to direct quality improvement efforts: Defining the highest impact complications after complex cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31628.
    PubMed     Abstract available


  155. MATSUO K, Machida H, Grubbs BH, Matsuzaki S, et al
    Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31482.
    PubMed     Abstract available


  156. KIM J, Cho YJ, Ryu JY, Hwang I, et al
    CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
    Gynecol Oncol. 2019 Nov 24. pii: S0090-8258(19)31625.
    PubMed     Abstract available


  157. COLLINS A, Miles GJ, Wood J, MacFarlane M, et al
    Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer.
    Gynecol Oncol. 2019 Nov 22. pii: S0090-8258(19)31671.
    PubMed     Abstract available


  158. MAI PL, Huang HQ, Wenzel LB, Han PK, et al
    Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.
    Gynecol Oncol. 2019 Nov 21. pii: S0090-8258(19)31613.
    PubMed     Abstract available


  159. STASENKO M, Tunnage I, Ashley CW, Rubinstein MM, et al
    Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
    Gynecol Oncol. 2019 Nov 19. pii: S0090-8258(19)31615.
    PubMed     Abstract available


  160. LE PAGE C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, et al
    Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
    Gynecol Oncol. 2019 Nov 18. pii: S0090-8258(19)31670.
    PubMed     Abstract available


  161. RODRIGUEZ-FREIXINOS V, Farinas-Madrid L, Gil-Martin M, Barretina-Ginesta P, et al
    Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277].
    Gynecol Oncol. 2019 Nov 16. pii: S0090-8258(19)31604.
    PubMed    


  162. TAYLOR SE, Chu T, Elvin JA, Edwards RP, et al
    Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
    Gynecol Oncol. 2019 Nov 15. pii: S0090-8258(19)31616.
    PubMed     Abstract available


  163. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Learning curve of high-complexity surgery for advanced ovarian cancer.
    Gynecol Oncol. 2019 Nov 14. pii: S0090-8258(19)31621.
    PubMed     Abstract available


  164. GAGNO S, Poletto E, Bartoletti M, Quartuccio L, et al
    A TGF-beta associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
    Gynecol Oncol. 2019 Nov 8. pii: S0090-8258(19)31603.
    PubMed     Abstract available


  165. MOORE KN, Miller A, Bell-McGuinn KM, Schilder RJ, et al
    A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
    Gynecol Oncol. 2019 Nov 7. pii: S0090-8258(19)31569.
    PubMed     Abstract available


  166. ALIMUJIANG A, Khoja L, Wiensch A, Pike MC, et al
    "I am not a statistic" ovarian cancer survivors' views of factors that influenced their long-term survival.
    Gynecol Oncol. 2019 Nov 6. pii: S0090-8258(19)31564.
    PubMed     Abstract available


  167. FEHNIGER JE, Berger AA, Juckett L, Elvin J, et al
    Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.
    Gynecol Oncol. 2019 Nov 5. pii: S0090-8258(19)31561.
    PubMed     Abstract available


  168. CECERE SC, Giannone G, Salutari V, Arenare L, et al
    Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
    Gynecol Oncol. 2019 Nov 4. pii: S0090-8258(19)31607.
    PubMed     Abstract available


  169. BEIRNE JP, McArt DG, Roddy A, McDermott C, et al
    Defining the molecular evolution of extrauterine high grade serous carcinoma.
    Gynecol Oncol. 2019;155:305-317.
    PubMed     Abstract available


  170. ONG PY, Poon SL, Tan KT, Putti TC, et al
    Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
    Gynecol Oncol. 2019;155:275-279.
    PubMed     Abstract available


    October 2019
  171. O'CEARBHAILL RE, Deng W, Chen LM, Lucci JA 3rd, et al
    A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: A
    Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31536.
    PubMed     Abstract available


  172. ALLDREDGE J, Serna-Gallegos T, Gallegos N, VanLeer JP, et al
    Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival.
    Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31565.
    PubMed    


  173. TATEBE K, Hasan Y, Son CH
    Adjuvant vaginal brachytherapy and chemotherapy versus pelvic radiotherapy in early-stage endometrial cancer: Outcomes by risk factors.
    Gynecol Oncol. 2019 Oct 11. pii: S0090-8258(19)31541.
    PubMed     Abstract available


  174. MARCHETTI C, Rosati A, Scaletta G, Pietragalla A, et al
    Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
    Gynecol Oncol. 2019 Oct 9. pii: S0090-8258(19)31545.
    PubMed     Abstract available


  175. BERG T, Nottrup TJ, Roed H
    Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31547.
    PubMed     Abstract available


  176. LABIDI-GALY SI, de La Motte Rouge T, Derbel O, Wolfer A, et al
    Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31528.
    PubMed     Abstract available


  177. KURODA T, Ogiwara H, Sasaki M, Takahashi K, et al
    Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31559.
    PubMed     Abstract available


    September 2019
  178. WONG JWH, Killeen JL, Carney ME
    Completeness of salpingectomy intended for ovarian cancer risk reduction.
    Gynecol Oncol. 2019 Sep 12. pii: S0090-8258(19)31523.
    PubMed     Abstract available


  179. DOCKERY LE, Rubenstein AR, Ding K, Mashburn SG, et al
    Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2019 Sep 12. pii: S0090-8258(19)31394.
    PubMed     Abstract available


  180. HIMOTO Y, Cybulska P, Shitano F, Sala E, et al
    Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?
    Gynecol Oncol. 2019 Sep 11. pii: S0090-8258(19)31462.
    PubMed     Abstract available


  181. VERGOTE I, du Bois A, Floquet A, Rau J, et al
    Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2019 Sep 10. pii: S0090-8258(19)31476.
    PubMed     Abstract available


  182. GRONWALD J, Lubinski J, Huzarski T, Cybulski C, et al
    A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.
    Gynecol Oncol. 2019 Sep 6. pii: S0090-8258(19)31486.
    PubMed     Abstract available


  183. HOLLIS RL, Stanley B, Iida Y, Thomson J, et al
    Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.
    Gynecol Oncol. 2019 Sep 5. pii: S0090-8258(19)31487.
    PubMed     Abstract available


  184. JOHANSEN G, Dahm-Kahler P, Staf C, Floter Radestad A, et al
    Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: Oncological and reproductive outcomes in a prospective nationwide population-based cohort study.
    Gynecol Oncol. 2019 Sep 4. pii: S0090-8258(19)31469.
    PubMed     Abstract available


  185. MAKII C, Ikeda Y, Oda K, Uehara Y, et al
    Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
    Gynecol Oncol. 2019 Sep 4. pii: S0090-8258(19)31480.
    PubMed     Abstract available


  186. KAY AH, Urban RR, Gray HJ
    Intraperitoneal ports placed at the time of bowel resection for treatment of ovarian cancer: Complications and surgical outcomes.
    Gynecol Oncol. 2019 Sep 3. pii: S0090-8258(19)31472.
    PubMed     Abstract available


    August 2019
  187. TOZZI R, Traill Z, Campanile RG, Kilic Y, et al
    Diagnostic flow-chart to identify bowel involvement in patients with stage IIIC-IV ovarian cancer: Can laparoscopy improve the accuracy of CT scan?
    Gynecol Oncol. 2019 Aug 31. pii: S0090-8258(19)31477.
    PubMed     Abstract available


  188. ELZAKKERS JCJ, van der Aa MA, van Altena AM, de Hullu JA, et al
    Further insights into the role of tumour characteristics in survival of young women with epithelial ovarian cancer.
    Gynecol Oncol. 2019 Aug 30. pii: S0090-8258(19)31470.
    PubMed     Abstract available


  189. LONG ROCHE K, Gardner GJ
    State of the science: Evolving role of surgery for the treatment of ovarian cancer.
    Gynecol Oncol. 2019 Aug 28. pii: S0090-8258(19)31468.
    PubMed    


  190. MATSUO K, Cripe JC, Kurnit KC, Kaneda M, et al
    Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer.
    Gynecol Oncol. 2019 Aug 16. pii: S0090-8258(19)31458.
    PubMed     Abstract available


  191. LIU YL, Zhou Q, Iasonos A, Emengo VN, et al
    Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer.
    Gynecol Oncol. 2019 Aug 14. pii: S0090-8258(19)31457.
    PubMed     Abstract available


  192. WEBBER K, Carolus E, Mileshkin L, Sommeijer D, et al
    OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors.
    Gynecol Oncol. 2019 Aug 12. pii: S0090-8258(19)31460.
    PubMed     Abstract available


  193. WADE KNS, Brady MF, Thai T, Wang Y, et al
    Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218.
    Gynecol Oncol. 2019 Aug 10. pii: S0090-8258(19)31409.
    PubMed     Abstract available


  194. KILTS TP, Glaser GE, Langstraat CL, Kumar A, et al
    Comparing risk stratification criteria for predicting lymphatic dissemination in endometrial cancer.
    Gynecol Oncol. 2019 Aug 10. pii: S0090-8258(19)31456.
    PubMed     Abstract available


  195. NARASIMHULU DM, Kumar A, Weaver AL, McGree ME, et al
    Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2019 Aug 8. pii: S0090-8258(19)31455.
    PubMed     Abstract available


  196. ZAMORANO AS, Hagemann AR, Morrison L, Lee JA, et al
    Pre-diagnosis body mass index, physical activity and ovarian cancer mortality.
    Gynecol Oncol. 2019 Aug 2. pii: S0090-8258(19)31449.
    PubMed     Abstract available


  197. SALYER C, Kobelka C, Barrie A, Weintraub MR, et al
    Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations.
    Gynecol Oncol. 2019;154:374-378.
    PubMed     Abstract available


    July 2019
  198. RANDALL LM, Wenham RM, Low PS, Dowdy SC, et al
    A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer.
    Gynecol Oncol. 2019 Jul 27. pii: S0090-8258(19)31396.
    PubMed     Abstract available


  199. RAMONDETTA LM, Hu W, Thaker PH, Urbauer DL, et al
    Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.
    Gynecol Oncol. 2019 Jul 25. pii: S0090-8258(19)31353.
    PubMed     Abstract available


  200. KATO K, Omi M, Fusegi A, Takeshima N, et al
    Modified posterior pelvic exenteration with pelvic side-wall resection requiring both intestinal and urinary reconstruction during surgery for ovarian cancer.
    Gynecol Oncol. 2019 Jul 24. pii: S0090-8258(19)31404.
    PubMed     Abstract available


  201. BARTELS HC, Rogers AC, McSharry V, McVey R, et al
    A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy.
    Gynecol Oncol. 2019 Jul 23. pii: S0090-8258(19)31397.
    PubMed     Abstract available


  202. CYBULSKA P, Paula ADC, Tseng J, Leitao MM Jr, et al
    Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
    Gynecol Oncol. 2019 Jul 21. pii: S0090-8258(19)31398.
    PubMed     Abstract available


  203. XIANG L, Ye S, Yang H
    Total pelvic peritonectomy for ovarian cancer with extensive peritoneal carcinomatosis in pelvic cavity.
    Gynecol Oncol. 2019 Jul 17. pii: S0090-8258(19)31352.
    PubMed     Abstract available


  204. HUBBARD AK, Poynter JN
    Global incidence comparisons and trends in ovarian germ cell tumors by geographic region in girls, adolescents and young women: 1988-2012.
    Gynecol Oncol. 2019 Jul 11. pii: S0090-8258(19)31348.
    PubMed     Abstract available


  205. MATSUO K, Huang Y, Zivanovic O, Shimada M, et al
    Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer.
    Gynecol Oncol. 2019 Jul 3. pii: S0090-8258(19)31337.
    PubMed     Abstract available


  206. KUMAR A, Sheedy S, Kim B, Suidan R, et al
    Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease.
    Gynecol Oncol. 2019;154:72-76.
    PubMed     Abstract available


    June 2019
  207. XIANG M, English DP, Kidd EA
    Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
    Gynecol Oncol. 2019 Jun 27. pii: S0090-8258(19)31336.
    PubMed     Abstract available


  208. KRANAWETTER M, Ataseven B, Grimm C, Schneider S, et al
    Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery.
    Gynecol Oncol. 2019 Jun 21. pii: S0090-8258(19)31331.
    PubMed     Abstract available


  209. CANAZ E, Grabowski JP, Richter R, Braicu EI, et al
    Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Gynecol Oncol. 2019 Jun 20. pii: S0090-8258(19)31327.
    PubMed     Abstract available


  210. HENGEVELD EM, Zusterzeel PLM, Lajer H, Hogdall CK, et al
    The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma.
    Gynecol Oncol. 2019 Jun 20. pii: S0090-8258(19)31317.
    PubMed     Abstract available


  211. FUH KC, Java JJ, Chan JK, Kapp DS, et al
    Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.
    Gynecol Oncol. 2019 Jun 19. pii: S0090-8258(19)31257.
    PubMed     Abstract available


  212. TANG M, O'Connell RL, Amant F, Beale P, et al
    PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
    Gynecol Oncol. 2019 Jun 18. pii: S0090-8258(19)31322.
    PubMed     Abstract available


  213. MARIANI A, Wang C, Oberg AL, Riska SM, et al
    Genes associated with bowel metastases in ovarian cancer.
    Gynecol Oncol. 2019 Jun 14. pii: S0090-8258(19)31321.
    PubMed     Abstract available


  214. DOTTINO JA, He W, Sun CC, Zhao H, et al
    Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes.
    Gynecol Oncol. 2019 Jun 14. pii: S0090-8258(19)31280.
    PubMed     Abstract available


  215. LIU JF, Gordon M, Veneris J, Braiteh F, et al
    Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
    Gynecol Oncol. 2019 Jun 13. pii: S0090-8258(19)31265.
    PubMed     Abstract available


  216. HORNER W, Peng K, Pleasant V, Brackmann M, et al
    Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Jun 11. pii: S0090-8258(19)31267.
    PubMed     Abstract available


  217. BOITANO TKL, Barrington DA, Batra S, McGwin G Jr, et al
    Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    Gynecol Oncol. 2019 Jun 10. pii: S0090-8258(19)31275.
    PubMed     Abstract available


  218. BERGAMINI A, Cormio G, Ferrandina G, Lorusso D, et al
    Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study.
    Gynecol Oncol. 2019 Jun 10. pii: S0090-8258(19)31273.
    PubMed     Abstract available


  219. HARDING BN, Delaney JA, Urban RR, Weiss NS, et al
    Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer.
    Gynecol Oncol. 2019 Jun 6. pii: S0090-8258(19)31274.
    PubMed     Abstract available


  220. FRAZER JL, Hook CE, Addley HC, Jackson CR, et al
    Recurrent ovarian immature teratoma in a 12-year-old girl: Implications for management.
    Gynecol Oncol. 2019 Jun 5. pii: S0090-8258(19)31277.
    PubMed     Abstract available


  221. MOORE KN, Gunderson CC, Sabbatini P, McMeekin DS, et al
    A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2019 Jun 4. pii: S0090-8258(19)30496.
    PubMed     Abstract available


  222. WRIGHT JD, Chen L, Buskwofie A, Tergas AI, et al
    Regionalization of care for women with ovarian cancer.
    Gynecol Oncol. 2019 Jun 3. pii: S0090-8258(19)31269.
    PubMed     Abstract available


  223. SHERMAN-SAMIS M, Onallah H, Holth A, Reich R, et al
    SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
    Gynecol Oncol. 2019;153:651-660.
    PubMed     Abstract available


    May 2019
  224. GRETTE K, Long B, Finan MA, Rocconi RP, et al
    Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a "second look".
    Gynecol Oncol. 2019 May 31. pii: S0090-8258(19)31236.
    PubMed     Abstract available


  225. NASIOUDIS D, Kahn R, Chapman-Davis E, Frey MK, et al
    Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.
    Gynecol Oncol. 2019 May 31. pii: S0090-8258(19)31260.
    PubMed     Abstract available


  226. NASIOUDIS D, Haggerty AF, Giuntoli RL 2nd, Burger RA, et al
    Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma.
    Gynecol Oncol. 2019 May 30. pii: S0090-8258(19)31233.
    PubMed     Abstract available


  227. COHEN PA, Powell A, Bohm S, Gilks CB, et al
    Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    Gynecol Oncol. 2019 May 19. pii: S0090-8258(19)31181.
    PubMed     Abstract available


  228. STASENKO M, Cybulska P, Feit N, Makker V, et al
    Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.
    Gynecol Oncol. 2019 May 18. pii: S0090-8258(19)31229.
    PubMed     Abstract available


  229. CHAPMAN BV, Swanick CW, Ning MS, Allen PK, et al
    Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.
    Gynecol Oncol. 2019 May 17. pii: S0090-8258(19)31227.
    PubMed     Abstract available


  230. GRANDI G, Perrone AM, Chiossi G, Friso S, et al
    Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study.
    Gynecol Oncol. 2019 May 16. pii: S0090-8258(19)31186.
    PubMed     Abstract available


  231. MARU Y, Tanaka N, Itami M, Hippo Y, et al
    Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
    Gynecol Oncol. 2019 May 14. pii: S0090-8258(19)31230.
    PubMed     Abstract available


  232. TOMAO F, Musacchio L, Di Mauro F, Boccia SM, et al
    Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
    Gynecol Oncol. 2019 May 9. pii: S0090-8258(19)30504.
    PubMed     Abstract available


  233. FILIPPOVA OT, Chi DS, Long Roche K, Sonoda Y, et al
    Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center.
    Gynecol Oncol. 2019 May 8. pii: S0090-8258(19)31185.
    PubMed     Abstract available


  234. VAN ARSDALE A, Miller DT, Kuo DY, Isani S, et al
    Association of obesity with survival in patients with endometrial cancer.
    Gynecol Oncol. 2019 May 3. pii: S0090-8258(19)30493.
    PubMed     Abstract available


  235. HOPPENOT C, Peters P, Cowan M, Moore ED, et al
    Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?
    Gynecol Oncol. 2019 May 2. pii: S0090-8258(19)31183.
    PubMed     Abstract available


  236. LEDERMANN JA
    Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
    Gynecol Oncol. 2019;153:213-214.
    PubMed    


  237. KRASNER CN, Castro C, Penson RT, Roche M, et al
    Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Mullerian origin.
    Gynecol Oncol. 2019;153:223-229.
    PubMed     Abstract available


    April 2019
  238. DANIELE G, Arenare L, Scambia G, Pisano C, et al
    Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
    Gynecol Oncol. 2019 Apr 24. pii: S0090-8258(19)30507.
    PubMed     Abstract available


  239. FRANCIS SR, Ager BJ, Do OA, Huang YJ, et al
    Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy.
    Gynecol Oncol. 2019 Apr 24. pii: S0090-8258(19)31174.
    PubMed     Abstract available


  240. KENNARD JA, Stephens AJ, Ahmad S, Zhu X, et al
    Sentinel lymph nodes (SLN) in endometrial cancer: The relationship between primary tumor histology, SLN metastasis size, and non-sentinel node metastasis.
    Gynecol Oncol. 2019 Apr 23. pii: S0090-8258(19)31152.
    PubMed     Abstract available


  241. GORE M, Hackshaw A, Brady WE, Penson RT, et al
    An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
    Gynecol Oncol. 2019 Apr 17. pii: S0090-8258(19)30491.
    PubMed     Abstract available


  242. ALHILLI MM, Elson P, Rybicki L, Khorana AA, et al
    Delay in time to surgery and impact on survival in patients with endometrial cancer: A National Cancer Database Analysis.
    Gynecol Oncol. 2019 Apr 15. pii: S0090-8258(19)30437.
    PubMed     Abstract available


  243. MOORE RG, Blackman A, Miller MC, Robison K, et al
    Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?
    Gynecol Oncol. 2019 Apr 13. pii: S0090-8258(19)30501.
    PubMed     Abstract available


  244. HORSBOEL TA, Kjaer SK, Johansen C, Suppli NP, et al
    Increased risk for depression persists for years among women treated for gynecological cancers - a register-based cohort study with up to 19years of follow-up.
    Gynecol Oncol. 2019 Apr 8. pii: S0090-8258(19)30494.
    PubMed     Abstract available


  245. REIJNEN C, Kusters-Vandevelde HVN, Prinsen CF, Massuger LFAG, et al
    Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.
    Gynecol Oncol. 2019 Apr 3. pii: S0090-8258(19)30270.
    PubMed     Abstract available


  246. LAGO V, Fotopoulou C, Chiantera V, Minig L, et al
    Risk factors for anastomotic leakage after colorectal resection in ovarian cancer surgery: A multi-centre study.
    Gynecol Oncol. 2019 Apr 2. pii: S0090-8258(19)30434.
    PubMed     Abstract available


  247. VAN BAAL JOAM, Van de Vijver KK, Algera MD, van der A MA, et al
    The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.
    Gynecol Oncol. 2019 Apr 1. pii: S0090-8258(19)30492.
    PubMed     Abstract available


  248. PUECHL AM, Edwards J, Suri A, Nakayama J, et al
    The association between progesterone receptor expression and survival in women with adult granulosa cell tumors.
    Gynecol Oncol. 2019;153:74-79.
    PubMed     Abstract available


  249. MANNING-GEIST BL, Alimena S, Del Carmen MG, Goodman A, et al
    Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter?
    Gynecol Oncol. 2019;153:63-67.
    PubMed     Abstract available


    March 2019
  250. COSGROVE CM, Cohn DE, Rhoades J, Felix AS, et al
    The prognostic significance of aortic lymph node metastasis in endometrial cancer: Potential implications for selective aortic lymph node assessment.
    Gynecol Oncol. 2019 Mar 30. pii: S0090-8258(19)30486.
    PubMed     Abstract available


  251. DE ARRUDA FN, Oonk MHM, Mourits MJE, de Graeff P, et al
    Determinants of health-related quality of life in elderly ovarian cancer patients: The role of frailty and dependence.
    Gynecol Oncol. 2019 Mar 29. pii: S0090-8258(19)30485.
    PubMed     Abstract available


  252. LAAKSONEN MA, Arriaga ME, Canfell K, MacInnis RJ, et al
    The preventable burden of endometrial and ovarian cancers in Australia: A pooled cohort study.
    Gynecol Oncol. 2019 Mar 29. pii: S0090-8258(19)30275.
    PubMed     Abstract available


  253. SECORD AA, McCollum M, Davidson BA, Broadwater G, et al
    Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
    Gynecol Oncol. 2019 Mar 28. pii: S0090-8258(19)30441.
    PubMed     Abstract available


  254. GUO Y, Cui W, Pei Y, Xu D, et al
    Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-beta signaling pathway.
    Gynecol Oncol. 2019 Mar 27. pii: S0090-8258(19)30136.
    PubMed     Abstract available


  255. DISILVESTRO PA
    Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years.
    Gynecol Oncol. 2019 Mar 22. pii: S0090-8258(19)30130.
    PubMed     Abstract available


  256. MORONEY MR, Davies KD, Wilberger AC, Sheeder J, et al
    Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
    Gynecol Oncol. 2019 Mar 22. pii: S0090-8258(19)30273.
    PubMed     Abstract available


  257. MACHIDA H, Matsuo K, Yamagami W, Ebina Y, et al
    Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study.
    Gynecol Oncol. 2019 Mar 21. pii: S0090-8258(19)30436.
    PubMed     Abstract available


  258. HEILMANN T, Pfisterer J, Hempel AM, Sass S, et al
    Early treatment modifications improve chemotherapy adherence in ovarian cancer patients >/=70years.
    Gynecol Oncol. 2019 Mar 21. pii: S0090-8258(19)30125.
    PubMed     Abstract available


  259. LAWRENSON K, Song F, Hazelett DJ, Kar SP, et al
    Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women.
    Gynecol Oncol. 2019 Mar 19. pii: S0090-8258(19)30133.
    PubMed     Abstract available


  260. HUANG M, Kamath P, Schlumbrecht M, Miao F, et al
    Identifying disparities in germline and somatic testing for ovarian cancer.
    Gynecol Oncol. 2019 Mar 16. pii: S0090-8258(19)30155.
    PubMed     Abstract available


  261. RATNER E, Bala M, Louie-Gao M, Aydin E, et al
    Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.
    Gynecol Oncol. 2019 Mar 12. pii: S0090-8258(19)30152.
    PubMed     Abstract available


  262. LAVIE O, Chetrit A, Novikov I, Sadetzki S, et al
    Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
    Gynecol Oncol. 2019 Mar 11. pii: S0090-8258(19)30132.
    PubMed     Abstract available


  263. MURAKAMI R, Matsumura N, Michimae H, Tanabe H, et al
    The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology G
    Gynecol Oncol. 2019 Mar 7. pii: S0090-8258(19)30120.
    PubMed     Abstract available


  264. SON JH, Kim J, Shim J, Kong TW, et al
    Comparison of posterior rectal dissection techniques during rectosigmoid colon resection as part of cytoreductive surgery in patients with epithelial ovarian cancer: Close rectal dissection versus total mesorectal excision.
    Gynecol Oncol. 2019 Mar 4. pii: S0090-8258(19)30139.
    PubMed     Abstract available


  265. MERT I, Kumar A, Torres D, Huang Y, et al
    Should mucosal bowel invasion in ovarian cancer be assigned to FIGO stage IV disease?
    Gynecol Oncol. 2019 Mar 2. pii: S0090-8258(19)30128.
    PubMed     Abstract available


  266. MEYER LA, Shi Q, Lasala J, Iniesta MD, et al
    Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery.
    Gynecol Oncol. 2019;152:501-508.
    PubMed     Abstract available


  267. KWON JS, Tinker AV, Hanley GE, Pansegrau G, et al
    BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
    Gynecol Oncol. 2019;152:459-464.
    PubMed     Abstract available


  268. TAYLOR JS, Zhang N, Rajan SS, Chavez-MacGregor M, et al
    How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients.
    Gynecol Oncol. 2019;152:452-458.
    PubMed     Abstract available


  269. FOOTE JR, Secord AA, Liang MI, Ehrisman JA, et al
    Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2019;152:445-451.
    PubMed     Abstract available


  270. FELDER M, Kapur A, Rakhmilevich AL, Qu X, et al
    MUC16 suppresses human and murine innate immune responses.
    Gynecol Oncol. 2019;152:618-628.
    PubMed     Abstract available


    February 2019
  271. TIMMERMANS M, van der Hel O, Sonke GS, Van de Vijver KK, et al
    The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review.
    Gynecol Oncol. 2019 Feb 27. pii: S0090-8258(19)30129.
    PubMed     Abstract available


  272. MORSE CB, Toukatly MN, Kilgore MR, Agnew KJ, et al
    Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
    Gynecol Oncol. 2019 Feb 22. pii: S0090-8258(19)30121.
    PubMed     Abstract available


  273. MCGUIRE S, Kara B, Hart PC, Montag A, et al
    Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30059.
    PubMed     Abstract available


  274. MATSUO K, Machida H, Mandelbaum RS, Grubbs BH, et al
    Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30106.
    PubMed     Abstract available


  275. MESQUITA KA, Alabdullah M, Griffin M, Toss MS, et al
    ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30124.
    PubMed     Abstract available


  276. VAN WALREE IC, Hamaker ME, van de Poll-Franse LV, Vos MC, et al
    Older ovarian cancer survivors report lower long-term health-related quality of life than younger survivors: A study from the population-based profiles registry.
    Gynecol Oncol. 2019 Feb 13. pii: S0090-8258(19)30104.
    PubMed     Abstract available


  277. NAUMANN RW, Coleman RL, Brown J, Moore KN, et al
    Phase III trials in ovarian cancer: The evolving landscape of front line therapy.
    Gynecol Oncol. 2019 Feb 12. pii: S0090-8258(19)30113.
    PubMed     Abstract available


  278. LIANG J, Wolsiefer K, Zestcott CA, Chase D, et al
    Implicit bias toward cervical cancer: Provider and training differences.
    Gynecol Oncol. 2019 Feb 7. pii: S0090-8258(19)30055.
    PubMed     Abstract available


  279. SUSZYNSKA M, Klonowska K, Jasinska AJ, Kozlowski P, et al
    Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
    Gynecol Oncol. 2019 Feb 4. pii: S0090-8258(19)30069.
    PubMed     Abstract available


  280. LIM SL, Havrilesky LJ, Habib AS, Secord AA, et al
    Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30067.
    PubMed     Abstract available


  281. VOGEL RI, Niendorf K, Petzel S, Lee H, et al
    A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30062.
    PubMed     Abstract available


  282. ORSULIC S, Karlan BY
    Can molecular subtyping be used to triage women with advanced ovarian cancer to Primary Debulking Surgery or Neoadjuvant Chemotherapy?
    Gynecol Oncol. 2019;152:221-222.
    PubMed    


  283. XIN W, Hua K, Ding J
    The way to display the chylous tubes and to prevent chylous leakage in laparoscopic para-aortic lymphadenectomy.
    Gynecol Oncol. 2019;152:434-435.
    PubMed    


  284. SMITH JA, Le T, Martin GA, Gaikwad A, et al
    Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia.
    Gynecol Oncol. 2019;152:265-269.
    PubMed     Abstract available


  285. FLEM KARLSEN K, McFadden E, Florenes VA, Davidson B, et al
    Soluble AXL is ubiquitously present in malignant serous effusions.
    Gynecol Oncol. 2019;152:408-415.
    PubMed     Abstract available


    January 2019
  286. HOSKINS P, Eccleston A, Hurry M, Dyer M, et al
    Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
    Gynecol Oncol. 2019 Jan 28. pii: S0090-8258(19)30061.
    PubMed     Abstract available


  287. MODUGNO F, Goughnour SL, Wallack D, Edwards RP, et al
    Breastfeeding factors and risk of epithelial ovarian cancer.
    Gynecol Oncol. 2019 Jan 25. pii: S0090-8258(19)30060.
    PubMed     Abstract available


  288. CHOI HJ, Heo JH, Park JY, Jeong JY, et al
    A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Gynecol Oncol. 2019 Jan 25. pii: S0090-8258(19)30045.
    PubMed     Abstract available


  289. HURLEY RM, Wahner Hendrickson AE, Visscher DW, Ansell P, et al
    53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    Gynecol Oncol. 2019 Jan 24. pii: S0090-8258(19)30058.
    PubMed     Abstract available


  290. UPPENDAHL LD, Felices M, Bendzick L, Ryan C, et al
    Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
    Gynecol Oncol. 2019 Jan 15. pii: S0090-8258(19)30039.
    PubMed     Abstract available


  291. DING J, Cheng XY, Liu S, Ji HY, et al
    Apatinib exerts anti-tumour effects on ovarian cancer cells.
    Gynecol Oncol. 2019 Jan 14. pii: S0090-8258(19)30043.
    PubMed     Abstract available


  292. BREGAR A, Mojtahed A, Kilcoyne A, Kurra V, et al
    CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Jan 11. pii: S0090-8258(18)31476.
    PubMed     Abstract available


  293. MCCUAIG JM, Tone AA, Maganti M, Romagnuolo T, et al
    Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study.
    Gynecol Oncol. 2019 Jan 10. pii: S0090-8258(18)31541.
    PubMed     Abstract available


  294. FABBRO M, Moore KN, Dorum A, Tinker AV, et al
    Efficacy and safety of niraparib as maintenance treatment in older patients (>/=70years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2019 Jan 9. pii: S0090-8258(18)31473.
    PubMed     Abstract available


  295. JERZAK KJ, Duska L, MacKay HJ
    Endocrine therapy in endometrial cancer: An old dog with new tricks.
    Gynecol Oncol. 2019 Jan 4. pii: S0090-8258(18)31518.
    PubMed     Abstract available


  296. YAO T, DeJong SR, McGree ME, Weaver AL, et al
    Frailty in ovarian cancer identified the need for increased postoperative care requirements following cytoreductive surgery.
    Gynecol Oncol. 2019 Jan 3. pii: S0090-8258(18)31539.
    PubMed     Abstract available


  297. SULLIVAN MW, Camacho FT, Mills AM, Modesitt SC, et al
    Missing information in statewide and national cancer databases: Correlation with health risk factors, geographic disparities, and outcomes.
    Gynecol Oncol. 2019;152:119-126.
    PubMed     Abstract available


    December 2018
  298. MATULONIS UA, Sill MW, Makker V, Mutch DG, et al
    A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Dec 23. pii: S0090-8258(18)31460.
    PubMed     Abstract available


  299. RAUH-HAIN JA, Hidrue MK, Gaccione P, Melamed A, et al
    Variation in resource utilization associated with the surgical management of ovarian cancer.
    Gynecol Oncol. 2018 Dec 19. pii: S0090-8258(18)31513.
    PubMed     Abstract available


  300. MYSONA D, Pyrzak A, Purohit S, Zhi W, et al
    A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer.
    Gynecol Oncol. 2018 Dec 18. pii: S0090-8258(18)31515.
    PubMed     Abstract available


  301. CEPPI L, Galli F, Lamanna M, Magni S, et al
    Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms.
    Gynecol Oncol. 2018 Dec 18. pii: S0090-8258(18)31452.
    PubMed     Abstract available


  302. NIE D, Gong H, Mao X, Li Z, et al
    Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31454.
    PubMed     Abstract available


  303. DAVIDSON BA, Broadwater G, Crim A, Boccacio R, et al
    Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31475.
    PubMed     Abstract available


  304. ANGELES MA, Martinez-Gomez C, Martinez A, Ferron G, et al
    En bloc pelvic resection for ovarian carcinomatosis: Hudson procedure in 10 steps.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31471.
    PubMed    


  305. RODRIGUEZ-FREIXINOS V, Farinas-Madrid L, Gil-Martin M, Barretina-Ginesta P, et al
    Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    Gynecol Oncol. 2018 Dec 12. pii: S0090-8258(18)31456.
    PubMed     Abstract available


  306. NORQUIST BM
    Challenges in the identification of inherited risk of ovarian cancer: where should we go from here?
    Gynecol Oncol. 2018 Dec 8. pii: S0090-8258(18)31459.
    PubMed    


  307. BEDNAR EM, Sun CC, Camacho B, Terrell J, et al
    Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic.
    Gynecol Oncol. 2018 Dec 8. pii: S0090-8258(18)31457.
    PubMed     Abstract available


  308. VARGA A, Piha-Paul S, Ott PA, Mehnert JM, et al
    Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
    Gynecol Oncol. 2018 Dec 3. pii: S0090-8258(18)31418.
    PubMed     Abstract available


    November 2018
  309. TORRES D, Kumar A, Bakkum-Gamez JN, Weaver AL, et al
    Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Nov 28. pii: S0090-8258(18)31420.
    PubMed     Abstract available


  310. HAY CM, Donovan HS, Campbell GB, Taylor SE, et al
    Chemotherapy in older adult gynecologic oncology patients: Can a phenotypic frailty score predict tolerance?
    Gynecol Oncol. 2018 Nov 28. pii: S0090-8258(18)31451.
    PubMed     Abstract available


  311. STANLEY B, Hollis RL, Nunes H, Towler JD, et al
    Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.
    Gynecol Oncol. 2018 Nov 27. pii: S0090-8258(18)31450.
    PubMed     Abstract available


  312. SUBRAMANIAM A, Einerson BD, Blanchard CT, Erickson BK, et al
    The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction.
    Gynecol Oncol. 2018 Nov 23. pii: S0090-8258(18)31405.
    PubMed     Abstract available


  313. WAGNER BE, Langstraat CL, McGree ME, Weaver AL, et al
    Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31422.
    PubMed     Abstract available


  314. JAVELLANA M, Hoppenot C, Lengyel E
    The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
    Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31404.
    PubMed     Abstract available


  315. BOLAND JL, Zhou Q, Martin M, Callahan MK, et al
    Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.
    Gynecol Oncol. 2018 Nov 20. pii: S0090-8258(18)31445.
    PubMed     Abstract available


  316. HEITZ F, Harter P, Avall-Lundqvist E, Reuss A, et al
    Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
    Gynecol Oncol. 2018 Nov 19. pii: S0090-8258(18)31406.
    PubMed     Abstract available


  317. PRADER S, Vollmar N, du Bois A, Heitz F, et al
    Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer.
    Gynecol Oncol. 2018 Nov 18. pii: S0090-8258(18)31363.
    PubMed     Abstract available


  318. GONZALEZ MARTIN A, Oza AM, Embleton AC, Pfisterer J, et al
    Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
    Gynecol Oncol. 2018 Nov 15. pii: S0090-8258(18)31166.
    PubMed     Abstract available


  319. ZHANG Q, Wang C, Cliby WA
    Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
    Gynecol Oncol. 2018 Nov 15. pii: S0090-8258(18)31415.
    PubMed     Abstract available


  320. KOTOULA V, Lakis S, Tikas I, Giannoulatou E, et al
    Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.
    Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31417.
    PubMed     Abstract available


  321. ROMEO C, Joly F, Ray-Coquard I, El Kouri C, et al
    Non-pegylated liposomal doxorubicin (NPLD, Myocet(R))+carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.
    Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31358.
    PubMed     Abstract available


  322. ZHONG Q, Hu Z, Li Q, Yi T, et al
    Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    Gynecol Oncol. 2018 Nov 7. pii: S0090-8258(18)31310.
    PubMed     Abstract available


  323. TURASHVILI G, Gomez-Hidalgo NR, Flynn J, Gonen M, et al
    Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.
    Gynecol Oncol. 2018 Nov 6. pii: S0090-8258(18)31315.
    PubMed     Abstract available


  324. LEE JY, Park JY, Park SY, Lee JW, et al
    Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
    Gynecol Oncol. 2018 Nov 5. pii: S0090-8258(18)31314.
    PubMed     Abstract available


  325. MULLEN MM, Kuroki LM, Thaker PH
    Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.
    Gynecol Oncol. 2018 Nov 5. pii: S0090-8258(18)31306.
    PubMed     Abstract available


  326. SELLA T, Stone RM
    The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence.
    Gynecol Oncol. 2018;151:187-189.
    PubMed    


    October 2018
  327. WANG Y, Jiang J, He L, Gong G, et al
    Effect of lamin-A expression on migration and nuclear stability of ovarian cancer cells.
    Gynecol Oncol. 2018 Oct 29. pii: S0090-8258(18)31313.
    PubMed     Abstract available


  328. HANSEN JM, Sood AK, Coleman RL, Westin SN, et al
    Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.
    Gynecol Oncol. 2018 Oct 23. pii: S0090-8258(18)31299.
    PubMed     Abstract available


  329. HINCHCLIFF E, Hong D, Le H, Chisholm G, et al
    Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.
    Gynecol Oncol. 2018 Oct 23. pii: S0090-8258(18)31287.
    PubMed     Abstract available


  330. OLAWAIYE AB, Java JJ, Krivak TC, Friedlander M, et al
    Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].
    Gynecol Oncol. 2018 Oct 22. pii: S0090-8258(18)31303.
    PubMed    


  331. TA RM, Hecht JL, Lin DI
    Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
    Gynecol Oncol. 2018 Oct 16. pii: S0090-8258(18)31291.
    PubMed     Abstract available


  332. TANNER EJ, Filippova OT, Gardner GJ, Long Roche KC, et al
    A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Oct 15. pii: S0090-8258(18)31285.
    PubMed     Abstract available


  333. CARTER NJ, Marshall ML, Susswein LR, Zorn KK, et al
    Germline pathogenic variants identified in women with ovarian tumors.
    Gynecol Oncol. 2018 Oct 12. pii: S0090-8258(18)31249.
    PubMed     Abstract available


  334. KIM HS, Kim JY, Lee YJ, Kim SH, et al
    Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 Oct 9. pii: S0090-8258(18)31153.
    PubMed     Abstract available


  335. NAUMANN RW, Morris JC, Tait DL, Higgins RV, et al
    Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer.
    Gynecol Oncol. 2018 Oct 8. pii: S0090-8258(18)31282.
    PubMed     Abstract available


  336. MONK BJ, Kauderer JT, Moxley KM, Bonebrake AJ, et al
    A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2018 Oct 8. pii: S0090-8258(18)31281.
    PubMed     Abstract available


  337. BELUR NAGARAJ A, Joseph P, Kovalenko O, Wang Q, et al
    Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.
    Gynecol Oncol. 2018 Oct 6. pii: S0090-8258(18)31238.
    PubMed     Abstract available


  338. WANG J, Dean DC, Hornicek FJ, Shi H, et al
    RNA sequencing (RNA-Seq) and its application in ovarian cancer.
    Gynecol Oncol. 2018 Oct 5. pii: S0090-8258(18)31283.
    PubMed     Abstract available


  339. WANG W, Zou W, Liu JR
    Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
    Gynecol Oncol. 2018;151:1-3.
    PubMed    


  340. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Successful retroperitoneal lymphadenectomy for double inferior vena cava with preoperative assessment using contrast-enhanced and three-dimensional computed tomography.
    Gynecol Oncol. 2018;151:180-181.
    PubMed    


    September 2018
  341. ELNAGGAR AC, Hade EM, O'Malley DM, Liang MI, et al
    Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.
    Gynecol Oncol. 2018 Sep 30. pii: S0090-8258(18)31233.
    PubMed     Abstract available


  342. NASSER S, Lathouras K, Nixon K, Campbell J, et al
    Impact of right upper quadrant cytoreductive techniques with extensive liver mobilization on postoperative hepatic function and risk of liver failure in patients with advanced ovarian cancer.
    Gynecol Oncol. 2018 Sep 29. pii: S0090-8258(18)31247.
    PubMed     Abstract available


  343. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Left cardiophrenic lymph node resection for advanced ovarian cancer with adhesion to the thoracic cavity.
    Gynecol Oncol. 2018 Sep 27. pii: S0090-8258(18)31241.
    PubMed    


  344. SHENOLIKAR R, Durden E, Meyer N, Lenhart G, et al
    Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
    Gynecol Oncol. 2018 Sep 26. pii: S0090-8258(18)31176.
    PubMed     Abstract available


  345. NIEMI RJ, Roine AN, Eraviita E, Kumpulainen PS, et al
    FAIMS analysis of urine gaseous headspace is capable of differentiating ovarian cancer.
    Gynecol Oncol. 2018 Sep 23. pii: S0090-8258(18)31235.
    PubMed     Abstract available


  346. TAYLOR JS, He W, Harrison R, Zhao H, et al
    Disparities in treatment and survival among elderly ovarian cancer patients.
    Gynecol Oncol. 2018 Sep 22. pii: S0090-8258(18)31171.
    PubMed     Abstract available


  347. ZIVANOVIC O, Chi DS, Filippova O, Randall LM, et al
    It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer.
    Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31218.
    PubMed     Abstract available


  348. HUA W, Zhao Y, Jin X, Yu D, et al
    METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.
    Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31234.
    PubMed     Abstract available


  349. WANG D, Cao D, Jia C, Huang H, et al
    Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors.
    Gynecol Oncol. 2018 Sep 12. pii: S0090-8258(18)31214.
    PubMed     Abstract available


  350. ODA K, Hamanishi J, Matsuo K, Hasegawa K, et al
    Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
    Gynecol Oncol. 2018 Sep 11. pii: S0090-8258(18)31174.
    PubMed     Abstract available


  351. AZIZ D, Etemadmoghadam D, Caldon CE, Au-Yeung G, et al
    19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
    Gynecol Oncol. 2018 Sep 9. pii: S0090-8258(18)31169.
    PubMed     Abstract available


  352. ZHAO H, Yu H, Zheng J, Ning N, et al
    Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5.
    Gynecol Oncol. 2018 Sep 7. pii: S0090-8258(18)31162.
    PubMed     Abstract available


  353. CONNOR JP, O'Shea A, McCool K, Sampene E, et al
    Peri-operative allogeneic blood transfusion is associated with poor overall survival in advanced epithelial ovarian Cancer; potential impact of patient blood management on Cancer outcomes.
    Gynecol Oncol. 2018 Sep 7. pii: S0090-8258(18)31170.
    PubMed     Abstract available


  354. RAJKUMAR S, Polson A, Nath R, Lane G, et al
    Prognostic implications of histological tumor regression (Bohm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Gynecol Oncol. 2018 Sep 6. pii: S0090-8258(18)31172.
    PubMed     Abstract available


  355. SCURRY J, van Zyl B, Gulliver D, Otton G, et al
    Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer.
    Gynecol Oncol. 2018 Sep 4. pii: S0090-8258(18)31160.
    PubMed     Abstract available


  356. MILLS KA, Roach ST, Quinn JM, Guo L, et al
    SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.
    Gynecol Oncol. 2018 Sep 3. pii: S0090-8258(18)31097.
    PubMed     Abstract available


  357. TSENG JH, Cowan RA, Afonso AM, Zhou Q, et al
    Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Sep 2. pii: S0090-8258(18)31154.
    PubMed     Abstract available


    August 2018
  358. TEW WP, Sill MW, Walker JL, Secord AA, et al
    Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31157.
    PubMed     Abstract available


  359. SCHLAPPE BA, Weaver AL, Ducie JA, Eriksson AGZ, et al
    Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy.
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31152.
    PubMed     Abstract available


  360. VAN NIEUWENHUYSEN E, Busschaert P, Neven P, Han SN, et al
    The genetic landscape of 87 ovarian germ cell tumors.
    Gynecol Oncol. 2018 Aug 28. pii: S0090-8258(18)31130.
    PubMed     Abstract available


  361. DIOUN S, Jorgensen JR, Miller EM, Tymon-Rosario J, et al
    Unplanned hospitalizations in a racially and ethnically diverse population of women receiving chemotherapy for epithelial ovarian cancer.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31150.
    PubMed     Abstract available


  362. CHANG JS, Kim SW, Kim YJ, Kim JY, et al
    Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31129.
    PubMed     Abstract available


  363. LYCKE M, Kristjansdottir B, Sundfeldt K
    A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31155.
    PubMed     Abstract available


  364. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Resection of a metastatic bulky subphrenic tumor for the treatment of advanced ovarian cancer using liver mobilization and the Pringle maneuver.
    Gynecol Oncol. 2018 Aug 20. pii: S0090-8258(18)31134.
    PubMed     Abstract available


  365. OLAWAIYE AB, Java JJ, Krivak TC, Friedlander M, et al
    Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Aug 19. pii: S0090-8258(18)31085.
    PubMed     Abstract available


  366. TSENG JH, Cowan RA, Zhou Q, Iasonos A, et al
    Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
    Gynecol Oncol. 2018 Aug 17. pii: S0090-8258(18)31131.
    PubMed     Abstract available


  367. SON JH, Lee JH, Jung JA, Kong TW, et al
    Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
    Gynecol Oncol. 2018 Aug 16. pii: S0090-8258(18)31098.
    PubMed     Abstract available


  368. PERES LC, Cushing-Haugen KL, Anglesio M, Wicklund K, et al
    Histotype classification of ovarian carcinoma: A comparison of approaches.
    Gynecol Oncol. 2018 Aug 15. pii: S0090-8258(18)31133.
    PubMed     Abstract available


  369. CONNOR EV, Newlin EM, Jelovsek JE, AlHilli MM, et al
    Predicting non-home discharge in epithelial ovarian cancer patients: External validation of a predictive model.
    Gynecol Oncol. 2018 Aug 11. pii: S0090-8258(18)31128.
    PubMed     Abstract available


  370. WINTERHOFF BJ, Maile M, Mitra AK, Sebe A, et al
    Corrigendum to "Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells" [Gyncol. Oncol. 144 (2017) 598-606].
    Gynecol Oncol. 2018 Aug 7. pii: S0090-8258(18)31079.
    PubMed    


  371. MOORE KN, O'Malley DM, Vergote I, Martin LP, et al
    Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2018 Aug 6. pii: S0090-8258(18)31081.
    PubMed     Abstract available


  372. MALLEN A, Soong TR, Townsend MK, Wenham RM, et al
    Surgical prevention strategies in ovarian cancer.
    Gynecol Oncol. 2018 Aug 4. pii: S0090-8258(18)31094.
    PubMed     Abstract available


  373. LI A, Xie R, Zhi Q, Deng Y, et al
    BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31088.
    PubMed     Abstract available


  374. PINTO MP, Balmaceda C, Bravo ML, Kato S, et al
    Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31089.
    PubMed     Abstract available


  375. LEVINE DA
    The limits of aggressive surgical cytoreduction.
    Gynecol Oncol. 2018;150:205-206.
    PubMed    


  376. MANNING-GEIST BL, Hicks-Courant K, Gockley AA, Clark RM, et al
    Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
    Gynecol Oncol. 2018;150:233-238.
    PubMed     Abstract available


  377. SHAH R, Xia C, Krailo M, Amatruda JF, et al
    Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
    Gynecol Oncol. 2018;150:253-260.
    PubMed     Abstract available


    July 2018
  378. BEHBAKHT K, Cohn DE, Straughn JM Jr
    Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.
    Gynecol Oncol. 2018 Jul 30. pii: S0090-8258(18)31083.
    PubMed    


  379. SONG M, Kumaran MN, Gounder M, Gibbon DG, et al
    Phase I trial of selenium plus chemotherapy in gynecologic cancers.
    Gynecol Oncol. 2018 Jul 29. pii: S0090-8258(18)31014.
    PubMed     Abstract available


  380. VERGOTE I, von Moos R, Manso L, Van Nieuwenhuysen E, et al
    Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
    Gynecol Oncol. 2018 Jul 27. pii: S0090-8258(18)31082.
    PubMed     Abstract available


  381. MEAGHER NS, Schuster K, Voss A, Budden T, et al
    Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
    Gynecol Oncol. 2018 Jul 24. pii: S0090-8258(18)31077.
    PubMed     Abstract available


  382. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Metastatic cardiophrenic lymph node resection following full-thickness resection of right diaphragm for advanced ovarian carcinoma.
    Gynecol Oncol. 2018 Jul 19. pii: S0090-8258(18)31067.
    PubMed     Abstract available


  383. BI Y, Verginadis II, Dey S, Lin L, et al
    Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    Gynecol Oncol. 2018 Jul 16. pii: S0090-8258(18)31015.
    PubMed     Abstract available


  384. TIMMERMANS M, van der Aa MA, Lalisang RI, Witteveen PO, et al
    Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31017.
    PubMed     Abstract available


  385. DENG K, Yang C, Tan Q, Song W, et al
    Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31004.
    PubMed     Abstract available


  386. BARNARD ME, Pyden A, Rice MS, Linares M, et al
    Inter-pathologist and pathology report agreement for ovarian tumor characteristics in the Nurses' Health Studies.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31016.
    PubMed     Abstract available


  387. BURGER RA, Deng W, Makker V, Collins Y, et al
    Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Jul 2. pii: S0090-8258(18)30999.
    PubMed     Abstract available


  388. SECORD AA, Previs RA, Nixon AB
    Cabozantinib in ovarian clear cell cancers: UnMET expectations.
    Gynecol Oncol. 2018;150:1-2.
    PubMed    


  389. CIUCCI A, Ferrandina G, Mascilini F, Filippetti F, et al
    Estrogen receptor beta: Potential target for therapy in adult granulosa cell tumors?
    Gynecol Oncol. 2018;150:158-165.
    PubMed     Abstract available


    June 2018
  390. MEYER LA, He W, Sun CC, Zhao H, et al
    Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness.
    Gynecol Oncol. 2018 Jun 29. pii: S0090-8258(18)31002.
    PubMed     Abstract available


  391. ZHANG XS, Zhang YM, Li B, Fan B, et al
    Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)30988.
    PubMed     Abstract available


  392. VERDOODT F, Dehlendorff C, Friis S, Kjaer SK, et al
    Non-aspirin NSAID use and ovarian cancer mortality.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)31000.
    PubMed     Abstract available


  393. GOCKLEY AA, Kolin DL, Awtrey CS, Lindeman NI, et al
    Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
    Gynecol Oncol. 2018 Jun 21. pii: S0090-8258(18)30937.
    PubMed     Abstract available


  394. ROSS MS, Burriss ME, Winger DG, Edwards RP, et al
    Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30984.
    PubMed     Abstract available


  395. CLARK RM, Rice LW, Del Carmen MG
    Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30985.
    PubMed     Abstract available


  396. URBAN RR, Pappas TC, Bullock RG, Munroe DG, et al
    Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30946.
    PubMed     Abstract available


  397. TORRES D, Wang C, Kumar A, Bakkum-Gamez JN, et al
    Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.
    Gynecol Oncol. 2018 Jun 17. pii: S0090-8258(18)30944.
    PubMed     Abstract available


  398. LI N, Zhan X, Zhan X
    The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes.
    Gynecol Oncol. 2018 Jun 16. pii: S0090-8258(18)30989.
    PubMed     Abstract available


  399. CHAN JK, Brady W, Monk BJ, Brown J, et al
    A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
    Gynecol Oncol. 2018 Jun 16. pii: S0090-8258(18)30941.
    PubMed     Abstract available


  400. GRAETZ I, Anderson JN, McKillop CN, Stepanski EJ, et al
    Use of a web-based app to improve postoperative outcomes for patients receiving gynecological oncology care: A randomized controlled feasibility trial.
    Gynecol Oncol. 2018 Jun 11. pii: S0090-8258(18)30983.
    PubMed     Abstract available


  401. WOOLDERINK JM, De Bock GH, de Hullu JA, Hollema H, et al
    Characteristics of Lynch syndrome associated ovarian cancer.
    Gynecol Oncol. 2018 Jun 4. pii: S0090-8258(18)30240.
    PubMed     Abstract available


    May 2018
  402. LINDEMANN K, Gao B, Mapagu C, Fereday S, et al
    Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30907.
    PubMed     Abstract available


  403. GIANNOPOULOU L, Mastoraki S, Buderath P, Strati A, et al
    ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30922.
    PubMed     Abstract available


  404. KOTSOPOULOS J, Gronwald J, Karlan B, Rosen B, et al
    Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2018 May 21. pii: S0090-8258(18)30898.
    PubMed     Abstract available


  405. MUELLER JJ, Schlappe BA, Kumar R, Olvera N, et al
    Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.
    Gynecol Oncol. 2018 May 21. pii: S0090-8258(18)30895.
    PubMed     Abstract available


  406. VON GRUENIGEN VE, Huang HQ, Cella D, Zevon M, et al
    Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 May 17. pii: S0090-8258(18)30904.
    PubMed     Abstract available


  407. O'SHEA A, McCool K, Harrison R, Sampene E, et al
    Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer.
    Gynecol Oncol. 2018 May 15. pii: S0090-8258(18)30901.
    PubMed     Abstract available


  408. RUSCITO I, Darb-Esfahani S, Kulbe H, Bellati F, et al
    The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2018 May 10. pii: S0090-8258(18)30892.
    PubMed     Abstract available


  409. BAERT T, Van Camp J, Vanbrabant L, Busschaert P, et al
    Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients.
    Gynecol Oncol. 2018 May 8. pii: S0090-8258(18)30891.
    PubMed     Abstract available


  410. NASIOUDIS D, Mastroyannis SA, Albright BB, Haggerty AF, et al
    Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes.
    Gynecol Oncol. 2018 May 8. pii: S0090-8258(18)30845.
    PubMed     Abstract available


  411. TEMPFER CB, Giger-Pabst U, Seebacher V, Petersen M, et al
    A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.
    Gynecol Oncol. 2018 May 6. pii: S0090-8258(18)30851.
    PubMed     Abstract available


  412. KONSTANTINOPOULOS PA, Brady WE, Farley J, Armstrong A, et al
    Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
    Gynecol Oncol. 2018 May 5. pii: S0090-8258(18)30850.
    PubMed     Abstract available


  413. NEBGEN DR, Hurteau J, Holman LL, Bradford A, et al
    Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
    Gynecol Oncol. 2018 May 4. pii: S0090-8258(18)30842.
    PubMed     Abstract available


    April 2018
  414. NISKAKOSKI A, Pasanen A, Porkka N, Eldfors S, et al
    Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas.
    Gynecol Oncol. 2018 Apr 28. pii: S0090-8258(18)30844.
    PubMed     Abstract available


  415. WANG J, Garbutt C, Ma H, Gao P, et al
    Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.
    Gynecol Oncol. 2018 Apr 23. pii: S0090-8258(18)30835.
    PubMed     Abstract available


  416. CHAPEL DB, Yamada SD, Cowan M, Lastra RR, et al
    Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
    Gynecol Oncol. 2018 Apr 13. pii: S0090-8258(18)30282.
    PubMed     Abstract available


  417. UYAR D, Neary J, Monroe A, Nugent M, et al
    Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.
    Gynecol Oncol. 2018 Apr 10. pii: S0090-8258(18)30239.
    PubMed     Abstract available


  418. LIU J, Nicum S, Reichardt P, Croitoru K, et al
    Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.
    Gynecol Oncol. 2018 Apr 4. pii: S0090-8258(18)30238.
    PubMed     Abstract available


  419. MANRRIQUEZ E, Chapman JS, Mak J, Blanco AM, et al
    Disparities in genetics assessment for women with ovarian cancer: Can we do better?
    Gynecol Oncol. 2018;149:84-88.
    PubMed     Abstract available


  420. DILLEY S, Erickson BK, Phillips CE, Kennemer CR, et al
    Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?
    Gynecol Oncol. 2018;149:49-52.
    PubMed     Abstract available


  421. COWAN RA, Tseng J, Ali N, Dearie H, et al
    Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center.
    Gynecol Oncol. 2018;149:43-48.
    PubMed     Abstract available


  422. MOORE KN, Mirza MR, Matulonis UA
    The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Gynecol Oncol. 2018;149:214-220.
    PubMed     Abstract available


    March 2018
  423. BONHOF CS, Mols F, Vos MC, Pijnenborg JMA, et al
    Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study.
    Gynecol Oncol. 2018 Mar 28. pii: S0090-8258(18)30232.
    PubMed     Abstract available


  424. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Efficacy of soft coagulation in retroperitoneal lymphadenectomy for ovarian cancer.
    Gynecol Oncol. 2018 Mar 21. pii: S0090-8258(18)30231.
    PubMed    


  425. LONG J, Zhu JY, Liu YB, Fu K, et al
    Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30176.
    PubMed     Abstract available


  426. MCDONALD JF
    Back to the future - The integration of big data with machine learning is re-establishing the importance of predictive correlations in ovarian cancer diagnostics and therapeutics.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30233.
    PubMed    


  427. WILSON AJ, Stubbs M, Liu P, Ruggeri B, et al
    The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30229.
    PubMed     Abstract available


  428. KIM J, Kim S, Lee HS, Yang W, et al
    Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30132.
    PubMed     Abstract available


  429. HAN C, Bellone S, Siegel ER, Altwerger G, et al
    A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30230.
    PubMed     Abstract available


  430. IDAHL A, Hermansson A, Lalos A
    Social support and ovarian cancer incidence - A Swedish prospective population-based study.
    Gynecol Oncol. 2018 Mar 17. pii: S0090-8258(18)30214.
    PubMed     Abstract available


  431. CARLTON AL, Illendula A, Gao Y, Llaneza DC, et al
    Small molecule inhibition of the CBFbeta/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.
    Gynecol Oncol. 2018 Mar 15. pii: S0090-8258(18)30174.
    PubMed     Abstract available


  432. ESKANDER RN, Kauderer J, Tewari KS, Mannel RS, et al
    Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30216.
    PubMed     Abstract available


  433. UCCELLA S, Mele MC, Quagliozzi L, Rinninella E, et al
    Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30215.
    PubMed     Abstract available


  434. MATSUO K, Yabuno A, Hom MS, Shida M, et al
    Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30131.
    PubMed     Abstract available


  435. GOSTNER JM, Obermayr E, Braicu IE, Concin N, et al
    Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.
    Gynecol Oncol. 2018 Mar 9. pii: S0090-8258(18)30139.
    PubMed     Abstract available


  436. SCHORGE JO, Bregar AJ, Durfee J, Berkowitz RS, et al
    Meigs to modern times: The evolution of debulking surgery in advanced ovarian cancer.
    Gynecol Oncol. 2018 Mar 7. pii: S0090-8258(18)30142.
    PubMed     Abstract available


  437. SCHUURMAN MS, Kruitwagen RFPM, Portielje JEA, Roes EM, et al
    Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis.
    Gynecol Oncol. 2018 Mar 4. pii: S0090-8258(18)30136.
    PubMed     Abstract available


  438. LIAO CI, Chow S, Chen LM, Kapp DS, et al
    Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US.
    Gynecol Oncol. 2018 Mar 4. pii: S0090-8258(18)30069.
    PubMed     Abstract available


  439. BUSKWOFIE A, Huang Y, Tergas AI, Hou JY, et al
    Impact of hospital volume on racial disparities and outcomes for endometrial cancer.
    Gynecol Oncol. 2018 Mar 2. pii: S0090-8258(18)30138.
    PubMed     Abstract available


  440. POWELL CB, Alabaster A, Stoller N, Armstrong MA, et al
    Bone loss in women with BRCA1 and BRCA2 mutations.
    Gynecol Oncol. 2018;148:535-539.
    PubMed     Abstract available


  441. FILIPPOV-LEVY N, Cohen-Schussheim H, Trope CG, Hetland Falkenthal TE, et al
    Expression and clinical role of long non-coding RNA in high-grade serous carcinoma.
    Gynecol Oncol. 2018;148:559-566.
    PubMed     Abstract available


    February 2018
  442. XIAO X, Dong D, He W, Song L, et al
    Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Gynecol Oncol. 2018 Feb 26. pii: S0090-8258(18)30128.
    PubMed     Abstract available


  443. WEAVER DT, Raphel TJ, Melamed A, Rauh-Hain JA, et al
    Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30126.
    PubMed     Abstract available


  444. BARRINGTON DA, Champion ML, Boitano TKL, Walters-Haygood CL, et al
    Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30133.
    PubMed     Abstract available


  445. HUVILA J, Laajala TD, Edqvist PH, Mardinoglu A, et al
    Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30135.
    PubMed     Abstract available


  446. JAREID M, Thalabard JC, Aarflot M, Bovelstad HM, et al
    Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.
    Gynecol Oncol. 2018 Feb 23. pii: S0090-8258(18)30125.
    PubMed     Abstract available


  447. KELLENBERGER LD, Petrik J
    Hyperglycemia promotes insulin-independent ovarian tumor growth.
    Gynecol Oncol. 2018 Feb 17. pii: S0090-8258(18)30122.
    PubMed     Abstract available


  448. OZA A, Kaye S, Van Tornout J, Sessa C, et al
    Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
    Gynecol Oncol. 2018 Feb 14. pii: S0090-8258(18)30058.
    PubMed     Abstract available


  449. LI Y, Wu T, Wang Y, Yang L, et al
    gamma-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
    Gynecol Oncol. 2018 Feb 8. pii: S0090-8258(18)30062.
    PubMed     Abstract available


  450. CRANE EK, Brown J
    Early stage mucinous ovarian cancer: A review.
    Gynecol Oncol. 2018 Feb 8. pii: S0090-8258(18)30074.
    PubMed     Abstract available


  451. DESAI P, Wallace R, Anderson ML, Howard BV, et al
    An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative.
    Gynecol Oncol. 2018 Feb 5. pii: S0090-8258(18)30038.
    PubMed     Abstract available


  452. SWANSON CL, Kumar A, Maharaj JM, Kemppainen JL, et al
    Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
    Gynecol Oncol. 2018 Feb 3. pii: S0090-8258(18)30072.
    PubMed     Abstract available


  453. MILLER KR, Patel JN, Zhang Q, Norris EJ, et al
    HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Gynecol Oncol. 2018 Feb 2. pii: S0090-8258(18)30061.
    PubMed     Abstract available


  454. NAUMANN RW, Brown J
    Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive?
    Gynecol Oncol. 2018 Feb 1. pii: S0090-8258(18)30068.
    PubMed     Abstract available


    January 2018
  455. DEWDNEY SB, Dancisak AC, Lachance JA, Grendys EC Jr, et al
    Society of Gynecologic Oncology Clinical Outcomes Registry: From small beginnings come great things.
    Gynecol Oncol. 2018 Jan 30. pii: S0090-8258(18)30060.
    PubMed     Abstract available


  456. KESSOUS R, Octeau D, Klein K, Tonin PN, et al
    Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
    Gynecol Oncol. 2018 Jan 29. pii: S0090-8258(18)30055.
    PubMed     Abstract available


  457. HENRY CE, Llamosas E, Daniels B, Coopes A, et al
    ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
    Gynecol Oncol. 2018 Jan 29. pii: S0090-8258(18)30064.
    PubMed     Abstract available


  458. NITECKI R, Diver EJ, Kamdar MM, Boruta DM 2nd, et al
    Patterns of palliative care referral in ovarian cancer: A single institution 5year retrospective analysis.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30056.
    PubMed     Abstract available


  459. SAMIMI G, Trabert B, Duggan MA, Robinson JL, et al
    Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.
    Gynecol Oncol. 2018 Jan 25. pii: S0090-8258(18)30048.
    PubMed     Abstract available


  460. GRAY HJ, Bell-McGuinn K, Fleming GF, Cristea M, et al
    Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gynecol Oncol. 2018 Jan 15. pii: S0090-8258(17)31620.
    PubMed     Abstract available


  461. BERGSTROM J, Aloisi A, Armbruster S, Yen TT, et al
    Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers.
    Gynecol Oncol. 2018 Jan 12. pii: S0090-8258(18)30002.
    PubMed     Abstract available


  462. TRABERT B, Aarestrup J, Ulrich LG, Wentzensen N, et al
    Birth weight and the risk of histological subtypes of ovarian and endometrial cancers: Results from the Copenhagen School Health Records Register.
    Gynecol Oncol. 2018 Jan 10. pii: S0090-8258(17)31622.
    PubMed     Abstract available


  463. SAED GM, Fletcher NM, Diamond MP, Morris RT, et al
    Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
    Gynecol Oncol. 2018 Jan 9. pii: S0090-8258(17)31606.
    PubMed     Abstract available


  464. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Retroperitoneal lymphadenectomy for ovarian cancer with double inferior vena cava.
    Gynecol Oncol. 2018 Jan 5. pii: S0090-8258(17)31619.
    PubMed    


  465. MUKERJI B, Baptiste C, Chen L, Tergas AI, et al
    Racial disparities in young women with endometrial cancer.
    Gynecol Oncol. 2018 Jan 4. pii: S0090-8258(17)31623.
    PubMed     Abstract available


    December 2017
  466. TOUHAMI O, Gregoire J, Renaud MC, Sebastianelli A, et al
    The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia.
    Gynecol Oncol. 2017 Dec 28. pii: S0090-8258(17)31617.
    PubMed     Abstract available


  467. SOISSON S, Ganz PA, Gaffney D, Rowe K, et al
    Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study.
    Gynecol Oncol. 2017 Dec 27. pii: S0090-8258(17)31616.
    PubMed     Abstract available


  468. GEPPERT B, Lonnerfors C, Bollino M, Persson J, et al
    Sentinel lymph node biopsy in endometrial cancer-Feasibility, safety and lymphatic complications.
    Gynecol Oncol. 2017 Dec 20. pii: S0090-8258(17)31602.
    PubMed     Abstract available


  469. TRAN AQ, Erim DO, Sullivan SA, Cole AL, et al
    Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
    Gynecol Oncol. 2017 Dec 19. pii: S0090-8258(17)31598.
    PubMed     Abstract available


  470. MIAO M, Deng G, Luo S, Zhou J, et al
    A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31596.
    PubMed     Abstract available


  471. BERNARDS SS, Pennington KP, Harrell MI, Agnew KJ, et al
    Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31551.
    PubMed     Abstract available


  472. KIM SI, Lee JW, Lee M, Kim HS, et al
    Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31552.
    PubMed     Abstract available


  473. SMITH D, Stewart CJR, Clarke EM, Lose F, et al
    ER and PR expression and survival after endometrial cancer.
    Gynecol Oncol. 2017 Dec 4. pii: S0090-8258(17)31537.
    PubMed     Abstract available


  474. URBAN RR, He H, Alfonso R, Hardesty MM, et al
    The end of life costs for Medicare patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Dec 3. pii: S0090-8258(17)31533.
    PubMed     Abstract available


  475. BITLER BG, Watson ZL, Wheeler LJ, Behbakht K, et al
    PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
    Gynecol Oncol. 2017;147:695-704.
    PubMed     Abstract available


  476. KUMAR A, Hurtt CC, Cliby WA, Martin JR, et al
    Concomitant venous thromboembolism at the time of primary EOC diagnosis: Perioperative outcomes and survival analyses.
    Gynecol Oncol. 2017;147:514-520.
    PubMed     Abstract available


  477. REISER E, Aust S, Seebacher V, Reinthaller A, et al
    Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses.
    Gynecol Oncol. 2017;147:690-694.
    PubMed     Abstract available


    November 2017
  478. HAMILTON CA, Miller A, Casablanca Y, Horowitz NS, et al
    Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.
    Gynecol Oncol. 2017 Nov 28. pii: S0090-8258(17)31528.
    PubMed     Abstract available


  479. ZHU J, Chen Z, Yong L
    Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer.
    Gynecol Oncol. 2017 Nov 27. pii: S0090-8258(17)31538.
    PubMed     Abstract available


  480. GULERIA S, Jensen A, Kjaer SK
    Risk of borderline ovarian tumors among women with benign ovarian tumors: A cohort study.
    Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31534.
    PubMed     Abstract available


  481. HOROWITZ NS, Larry Maxwell G, Miller A, Hamilton CA, et al
    Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.
    Gynecol Oncol. 2017 Nov 22. pii: S0090-8258(17)31371.
    PubMed     Abstract available


  482. LEE YJ, Chung YS, Lee JY, Nam EJ, et al
    Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Nov 21. pii: S0090-8258(17)31532.
    PubMed     Abstract available


  483. TOZZI R, Casarin J, Garruto-Campanile R, Majd HS, et al
    Morbidity and reversal rate of ileostomy after bowel resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer.
    Gynecol Oncol. 2017 Nov 20. pii: S0090-8258(17)31527.
    PubMed     Abstract available


  484. HEINZELMANN-SCHWARZ V, Knipprath Meszaros A, Stadlmann S, Jacob F, et al
    Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
    Gynecol Oncol. 2017 Nov 17. pii: S0090-8258(17)31458.
    PubMed     Abstract available


  485. CHAMPER M, Huang Y, Hou JY, Tergas AI, et al
    Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence.
    Gynecol Oncol. 2017 Nov 15. pii: S0090-8258(17)31504.
    PubMed     Abstract available


  486. SHAH JS, Gard GB, Yang J, Maidens J, et al
    Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer.
    Gynecol Oncol. 2017 Nov 10. pii: S0090-8258(17)31500.
    PubMed     Abstract available


  487. COSGROVE CM, Tritchler DL, Cohn DE, Mutch DG, et al
    An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
    Gynecol Oncol. 2017 Nov 10. pii: S0090-8258(17)31459.
    PubMed     Abstract available


  488. TIMMERMANS M, Schuurman MS, Ho VKY, Massuger LF, et al
    Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery.
    Gynecol Oncol. 2017 Nov 9. pii: S0090-8258(17)31505.
    PubMed     Abstract available


  489. MERT I, Kumar A, Sheedy SP, Weaver AL, et al
    Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival.
    Gynecol Oncol. 2017 Nov 9. pii: S0090-8258(17)31446.
    PubMed     Abstract available


  490. HOPPENOT C, Eckert MA, Tienda SM, Lengyel E, et al
    Who are the long-term survivors of high grade serous ovarian cancer?
    Gynecol Oncol. 2017 Nov 8. pii: S0090-8258(17)31454.
    PubMed     Abstract available


  491. HINCHCLIFF E, Melamed A, Bregar A, Diver E, et al
    Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
    Gynecol Oncol. 2017 Nov 8. pii: S0090-8258(17)31460.
    PubMed     Abstract available


  492. CHAN JK, Kapp DS
    Clear Cell Ovarian Cancer: Optimum Management and Prognosis Remain Hazy.
    Gynecol Oncol. 2017;147:237-239.
    PubMed    


  493. ALTMAN AD, McGee J, May T, Lane K, et al
    Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study.
    Gynecol Oncol. 2017;147:257-261.
    PubMed     Abstract available


    October 2017
  494. RONCOLATO FT, Berton-Rigaud D, O'Connell R, Lanceley A, et al
    Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
    Gynecol Oncol. 2017 Oct 26. pii: S0090-8258(17)31422.
    PubMed     Abstract available


  495. LIN DI, Chudnovsky Y, Duggan B, Zajchowski D, et al
    Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
    Gynecol Oncol. 2017 Oct 25. pii: S0090-8258(17)31355.
    PubMed     Abstract available


  496. SHALOWITZ DI, Nivasch E, Burger RA, Schapira MM, et al
    Are patients willing to travel for better ovarian cancer care?
    Gynecol Oncol. 2017 Oct 24. pii: S0090-8258(17)31421.
    PubMed     Abstract available


  497. YI Y, Tsai SH, Cheng JC, Wang EY, et al
    APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner.
    Gynecol Oncol. 2017 Oct 24. pii: S0090-8258(17)31419.
    PubMed     Abstract available


  498. JONES MR, Kamara D, Karlan BY, Pharoah PDP, et al
    Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction.
    Gynecol Oncol. 2017 Oct 17. pii: S0090-8258(17)31361.
    PubMed     Abstract available


  499. ARIMA R, Hautakoski A, Marttila M, Arffman M, et al
    Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication.
    Gynecol Oncol. 2017 Oct 17. pii: S0090-8258(17)31417.
    PubMed     Abstract available


  500. DOCKERY LE, Tew WP, Ding K, Moore KN, et al
    Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Oct 13. pii: S0090-8258(17)31364.
    PubMed     Abstract available


  501. SCHULTZ KAP, Harris AK, Finch M, Dehner LP, et al
    DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry.
    Gynecol Oncol. 2017 Oct 13. pii: S0090-8258(17)31358.
    PubMed     Abstract available


  502. POZZAR RA, Berry DL
    Patient-centered research priorities in ovarian cancer: A systematic review of potential determinants of guideline care.
    Gynecol Oncol. 2017 Oct 10. pii: S0090-8258(17)31365.
    PubMed     Abstract available


  503. XIA Z, Cochrane DR, Anglesio MS, Wang YK, et al
    LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31356.
    PubMed     Abstract available


  504. NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
    Fertility-preserving surgery for advanced stage ovarian germ cell tumors.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31370.
    PubMed     Abstract available


  505. PEPIN K, Bregar A, Davis M, Melamed A, et al
    Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
    Gynecol Oncol. 2017 Oct 4. pii: S0090-8258(17)31352.
    PubMed     Abstract available


  506. MATSUO K, Machida H, Frimer M, Marcus JZ, et al
    Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer.
    Gynecol Oncol. 2017 Oct 3. pii: S0090-8258(17)31351.
    PubMed     Abstract available


    September 2017
  507. DEVOR EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, et al
    Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Sep 29. pii: S0090-8258(17)31349.
    PubMed     Abstract available


  508. DUCIE JA, Eriksson AGZ, Ali N, McGree ME, et al
    Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease.
    Gynecol Oncol. 2017 Sep 28. pii: S0090-8258(17)31354.
    PubMed     Abstract available


  509. QIU C, Lu N, Wang X, Zhang Q, et al
    Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
    Gynecol Oncol. 2017 Sep 28. pii: S0090-8258(17)31353.
    PubMed     Abstract available


  510. TORRES D, Kumar A, Wallace SK, Bakkum-Gamez JN, et al
    Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer.
    Gynecol Oncol. 2017 Sep 27. pii: S0090-8258(17)31345.
    PubMed     Abstract available


  511. BARBER EL, Rossi EC, Gehrig PA
    Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?
    Gynecol Oncol. 2017 Sep 20. pii: S0090-8258(17)31340.
    PubMed     Abstract available


  512. RUSTIN G, Vergote I, Micha JP, Duska LR, et al
    A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31264.
    PubMed     Abstract available


  513. MOORE KN, Tritchler D, Kaufman KM, Lankes H, et al
    Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31261.
    PubMed     Abstract available


  514. LILYQUIST J, LaDuca H, Polley E, Davis BT, et al
    Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls.
    Gynecol Oncol. 2017 Sep 7. pii: S0090-8258(17)31268.
    PubMed     Abstract available


  515. PISU M, Kenzik KM, Rim SH, Funkhouser EM, et al
    Values and worries of ovarian cancer patients.
    Gynecol Oncol. 2017 Sep 6. pii: S0090-8258(17)31267.
    PubMed     Abstract available


  516. COWAN RA, Tseng J, Murthy V, Srivastava R, et al
    Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.
    Gynecol Oncol. 2017 Sep 6. pii: S0090-8258(17)31270.
    PubMed     Abstract available


  517. OZA AM, Tinker AV, Oaknin A, Shapira-Frommer R, et al
    Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
    Gynecol Oncol. 2017 Sep 4. pii: S0090-8258(17)31260.
    PubMed     Abstract available


  518. HAVRILESKY LJ
    The costs of adding laparoscopy to the management of advanced stage epithelial ovarian cancer.
    Gynecol Oncol. 2017;146:441-442.
    PubMed    


    August 2017
  519. WANG X, Ivan M, Hawkins SM
    The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.
    Gynecol Oncol. 2017 Aug 30. pii: S0090-8258(17)31266.
    PubMed     Abstract available


  520. ZHU Z, Lou C, Zheng Z, Zhu R, et al
    ZFP403, a novel tumor suppressor, inhibits the proliferation and metastasis in ovarian cancer.
    Gynecol Oncol. 2017 Aug 30. pii: S0090-8258(17)31263.
    PubMed     Abstract available


  521. LAGO V, Domingo S, Matute L, Padilla P, et al
    Ghost ileostomy in advanced ovarian cancer.
    Gynecol Oncol. 2017 Aug 29. pii: S0090-8258(17)31255.
    PubMed    


  522. GOFF BA, Agnew K, Neradilek MB, Gray HJ, et al
    Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.
    Gynecol Oncol. 2017 Aug 28. pii: S0090-8258(17)31258.
    PubMed     Abstract available


  523. DUAN H, Yan Z, Chen W, Wu Y, et al
    TET1 inhibits EMT of ovarian cancer cells through activating Wnt/beta-catenin signaling inhibitors DKK1 and SFRP2.
    Gynecol Oncol. 2017 Aug 26. pii: S0090-8258(17)31248.
    PubMed     Abstract available


  524. HERZOG TJ, Ison G, Alvarez RD, Balasubramaniam S, et al
    FDA ovarian cancer clinical trial endpoints workshop.
    Gynecol Oncol. 2017 Aug 24. pii: S0090-8258(17)31250.
    PubMed    


  525. MARTIN LP, Konner JA, Moore KN, Seward SM, et al
    Characterization of folate receptor alpha (FRalpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRalpha-targeting antibody-drug conjugate mirvetuximab soravtansine.
    Gynecol Oncol. 2017 Aug 24. pii: S0090-8258(17)31253.
    PubMed     Abstract available


  526. PEARL ML, Dong H, Zhao Q, Tulley S, et al
    iCTC drug resistance (CDR) Testing ex vivo for evaluation of available therapies to treat patients with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Aug 19. pii: S0090-8258(17)31256.
    PubMed     Abstract available


  527. MELAMED A, Manning-Geist B, Bregar AJ, Diver EJ, et al
    Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Gynecol Oncol. 2017 Aug 16. pii: S0090-8258(17)31225.
    PubMed     Abstract available


  528. OLIVER KE, Brady WE, Birrer M, Gershenson DM, et al
    An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
    Gynecol Oncol. 2017 Aug 11. pii: S0090-8258(17)31226.
    PubMed     Abstract available


  529. NASIOUDIS D, Chapman-Davis E, Frey MK, Caputo TA, et al
    Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base.
    Gynecol Oncol. 2017 Aug 10. pii: S0090-8258(17)31251.
    PubMed     Abstract available


  530. THAKER PH, Brady WE, Lankes HA, Odunsi K, et al
    A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary perito
    Gynecol Oncol. 2017 Aug 9. pii: S0090-8258(17)31186.
    PubMed     Abstract available


  531. FORTNER RT, Damms-Machado A, Kaaks R
    Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
    Gynecol Oncol. 2017 Aug 8. pii: S0090-8258(17)31178.
    PubMed     Abstract available


  532. KNAPP P, Bodnar L, Blachnio-Zabielska A, Swiderska M, et al
    Plasma and ovarian tissue sphingolipids profiling in patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Aug 8. pii: S0090-8258(17)31183.
    PubMed     Abstract available


  533. TATE S, Kato K, Nishikimi K, Matsuoka A, et al
    Survival and safety associated with aggressive surgery for stage III/IV epithelial ovarian cancer: A single institution observation study.
    Gynecol Oncol. 2017 Aug 8. pii: S0090-8258(17)31176.
    PubMed     Abstract available


  534. BOGANI G, Tagliabue E, Ditto A, Signorelli M, et al
    Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses.
    Gynecol Oncol. 2017 Aug 2. pii: S0090-8258(17)31179.
    PubMed     Abstract available


  535. CRIM A, Rowland M, Ruskin R, Dvorak J, et al
    Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
    Gynecol Oncol. 2017;146:268-272.
    PubMed     Abstract available


    July 2017
  536. CHOI C, Kim WY, Lee DH, Oh SS, et al
    Cytoreduction of bulky para-aortic lymphadenopathy from metastatic ovarian cancer.
    Gynecol Oncol. 2017 Jul 31. pii: S0090-8258(17)31173.
    PubMed    


  537. FLEMING ND, Coleman RL, Tung C, Westin SN, et al
    Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Jul 31. pii: S0090-8258(17)31177.
    PubMed     Abstract available


  538. FADER AN, Bergstrom J, Jernigan A, Tanner EJ 3rd, et al
    Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
    Gynecol Oncol. 2017 Jul 30. pii: S0090-8258(17)31167.
    PubMed     Abstract available


  539. HOGEN L, Brar H, Covens A, Bassiouny D, et al
    Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma?
    Gynecol Oncol. 2017 Jul 28. pii: S0090-8258(17)31168.
    PubMed     Abstract available


  540. COHN DE, Sill MW, Walker JL, O'Malley D, et al
    Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin(R)) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Jul 27. pii: S0090-8258(17)31175.
    PubMed     Abstract available


  541. MILLER EM, Tymon-Rosario J, Xie X, Xue X, et al
    Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.
    Gynecol Oncol. 2017 Jul 24. pii: S0090-8258(17)31169.
    PubMed     Abstract available


  542. PHIPPEN NT, Secord AA, Wolf S, Samsa G, et al
    Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.
    Gynecol Oncol. 2017 Jul 22. pii: S0090-8258(17)31138.
    PubMed     Abstract available


  543. ADAM JP, Boumedien F, Letarte N, Provencher D, et al
    Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
    Gynecol Oncol. 2017 Jul 21. pii: S0090-8258(17)31160.
    PubMed     Abstract available


  544. KUMAR A, Langstraat CL, DeJong SR, McGree ME, et al
    Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer.
    Gynecol Oncol. 2017 Jul 19. pii: S0090-8258(17)31163.
    PubMed     Abstract available


  545. KHATIB G, Guzel AB, Gulec UK, Vardar MA, et al
    A novel technique: Carbon dioxide gas-assisted total peritonectomy, diaphragm and intestinal meso stripping in open surgery for advanced ovarian cancer (Cukurova technique).
    Gynecol Oncol. 2017 Jul 15. pii: S0090-8258(17)31172.
    PubMed     Abstract available


  546. FALCONE F, Scambia G, Benedetti Panici P, Signorelli M, et al
    Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
    Gynecol Oncol. 2017 Jul 14. pii: S0090-8258(17)31025.
    PubMed     Abstract available


  547. NASIOUDIS D, Chapman-Davis E, Frey MK, Caputo TA, et al
    Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB?
    Gynecol Oncol. 2017 Jul 14. pii: S0090-8258(17)31161.
    PubMed     Abstract available


  548. PALEARI L, Gandini S, Provinciali N, Puntoni M, et al
    Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis.
    Gynecol Oncol. 2017 Jul 10. pii: S0090-8258(17)30977.
    PubMed     Abstract available


  549. MENDERES G, Bonazzoli E, Bellone S, Altwerger G, et al
    Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.
    Gynecol Oncol. 2017 Jul 10. pii: S0090-8258(17)31026.
    PubMed     Abstract available


  550. KRISTELEIT R, Davidenko I, Shirinkin V, El-Khouly F, et al
    A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
    Gynecol Oncol. 2017 Jul 8. pii: S0090-8258(17)31022.
    PubMed     Abstract available


  551. YUAN X, Zhang J, Li D, Mao Y, et al
    Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2017 Jul 8. pii: S0090-8258(17)31024.
    PubMed     Abstract available


  552. GREENWADE MM, Moore KN, Gillen JM, Ding K, et al
    Factors influencing clinical trial enrollment among ovarian cancer patients.
    Gynecol Oncol. 2017 Jul 6. pii: S0090-8258(17)30976.
    PubMed     Abstract available


  553. MATZ M, Coleman MP, Carreira H, Salmeron D, et al
    Erratum to "Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 396-404].
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30974.
    PubMed    


  554. SON JH, Chang SJ, Ryu HS
    Porta hepatis debulking procedures as part of primary cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30978.
    PubMed     Abstract available


  555. MATZ M, Coleman MP, Sant M, Chirlaque MD, et al
    Erratum to "The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 405-413].
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30973.
    PubMed    


    June 2017
  556. KAWABATA A, Yanaihara N, Nagata C, Saito M, et al
    Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
    Gynecol Oncol. 2017 Jun 30. pii: S0090-8258(17)30968.
    PubMed     Abstract available


  557. SUN Z, Gilbert L, Ciampi A, Basso O, et al
    Recruitment challenges in clinical research: Survey of potential participants in a diagnostic study of ovarian cancer.
    Gynecol Oncol. 2017 Jun 27. pii: S0090-8258(17)30962.
    PubMed     Abstract available


  558. VAN DE VRIE R, van Meurs HS, Rutten MJ, Naaktgeboren CA, et al
    Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer.
    Gynecol Oncol. 2017 Jun 20. pii: S0090-8258(17)30960.
    PubMed     Abstract available


  559. ARIMA R, Marttila M, Hautakoski A, Arffman M, et al
    Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes.
    Gynecol Oncol. 2017 Jun 20. pii: S0090-8258(17)30952.
    PubMed     Abstract available


  560. MOSS HA, Havrilesky LJ, Chino J
    Insurance coverage among women diagnosed with a gynecologic malignancy before and after implementation of the Affordable Care Act.
    Gynecol Oncol. 2017 Jun 19. pii: S0090-8258(17)30953.
    PubMed     Abstract available


  561. SOOVARES P, Pasanen A, Butzow R, Lassus H, et al
    L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
    Gynecol Oncol. 2017 Jun 15. pii: S0090-8258(17)30939.
    PubMed     Abstract available


  562. SZENDER JB, Emmons T, Belliotti S, Dickson D, et al
    Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study.
    Gynecol Oncol. 2017 Jun 14. pii: S0090-8258(17)30937.
    PubMed     Abstract available


  563. BEDNAR EM, Oakley HD, Sun CC, Burke CC, et al
    A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
    Gynecol Oncol. 2017 Jun 10. pii: S0090-8258(17)30893.
    PubMed     Abstract available


  564. GRIMM C, Harter P, Alesina PF, Prader S, et al
    The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery.
    Gynecol Oncol. 2017 Jun 10. pii: S0090-8258(17)30936.
    PubMed     Abstract available


  565. FREY MK, Ellis AE, Koontz LM, Shyne S, et al
    Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum.
    Gynecol Oncol. 2017 Jun 8. pii: S0090-8258(17)30885.
    PubMed     Abstract available



  566. A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer.
    Gynecol Oncol. 2017 Jun 7. pii: S0090-8258(17)30895.
    PubMed     Abstract available


  567. VOGEL TJ, Goodman MT, Li AJ, Jeon CY, et al
    Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Jun 5. pii: S0090-8258(17)30848.
    PubMed     Abstract available


  568. RANDALL LM, Pothuri B, Swisher EM, Diaz JP, et al
    Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper.
    Gynecol Oncol. 2017 Jun 5. pii: S0090-8258(17)30897.
    PubMed     Abstract available


  569. SINNO AK, Li X, Thompson RE, Tanner EJ 3rd, et al
    Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care.
    Gynecol Oncol. 2017;145:493-499.
    PubMed     Abstract available


  570. BRACHOVA P, Alvarez NS, Van Voorhis BJ, Christenson LK, et al
    Cytidine deaminase Apobec3a induction in fallopian epithelium after exposure to follicular fluid.
    Gynecol Oncol. 2017;145:577-583.
    PubMed     Abstract available


  571. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Complete resection of locally advanced ovarian carcinoma fixed to the pelvic sidewall and involving external and internal iliac vessels.
    Gynecol Oncol. 2017 Jun 1. pii: S0090-8258(17)30887.
    PubMed     Abstract available


    May 2017
  572. DILLEY SE, Havrilesky LJ, Bakkum-Gamez J, Cohn DE, et al
    Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention.
    Gynecol Oncol. 2017 May 31. pii: S0090-8258(17)30890.
    PubMed     Abstract available


  573. PLANTE M, Stanleigh J, Renaud MC, Sebastianelli A, et al
    Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter?
    Gynecol Oncol. 2017 May 31. pii: S0090-8258(17)30880.
    PubMed     Abstract available


  574. HOLLOWAY RW, Abu-Rustum NR, Backes FJ, Boggess JF, et al
    Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations.
    Gynecol Oncol. 2017 May 28. pii: S0090-8258(17)30883.
    PubMed     Abstract available


  575. EGGINK FA, Mom CH, Boll D, Ezendam NPM, et al
    Compliance with adjuvant treatment guidelines in endometrial cancer: room for improvement in high risk patients.
    Gynecol Oncol. 2017 May 25. pii: S0090-8258(17)30881.
    PubMed     Abstract available


  576. JAMIESON A, Sykes P, Eva L, Bergzoll C, et al
    Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence.
    Gynecol Oncol. 2017 May 23. pii: S0090-8258(17)30879.
    PubMed     Abstract available


  577. MALAGON-BLACKWELL EM, Seagle BL, Nieves-Neira W, Shahabi S, et al
    The Hispanic Paradox in endometrial cancer: A National Cancer Database study.
    Gynecol Oncol. 2017 May 23. pii: S0090-8258(17)30882.
    PubMed     Abstract available


  578. FABER MT, Frederiksen K, Jensen A, Aarslev PB, et al
    Time trends in the incidence of hysterectomy-corrected overall, type 1 and type 2 endometrial cancer in Denmark 1978-2014.
    Gynecol Oncol. 2017 May 23. pii: S0090-8258(17)30854.
    PubMed     Abstract available


  579. MERT I, Chhina J, Allo G, Dai J, et al
    Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
    Gynecol Oncol. 2017 May 22. pii: S0090-8258(17)30871.
    PubMed     Abstract available


  580. SEAGLE BL, Ann P, Butler S, Shahabi S, et al
    Ovarian granulosa cell tumor: A National Cancer Database study.
    Gynecol Oncol. 2017 May 19. pii: S0090-8258(17)30873.
    PubMed     Abstract available


  581. REYES HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, et al
    High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
    Gynecol Oncol. 2017 May 19. pii: S0090-8258(17)30870.
    PubMed     Abstract available


  582. DINKIC C, Eichbaum M, Schmidt M, Grischke EM, et al
    Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
    Gynecol Oncol. 2017 May 18. pii: S0090-8258(17)30852.
    PubMed     Abstract available


  583. SOLIMAN PT, Westin SN, Dioun S, Sun CC, et al
    A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer.
    Gynecol Oncol. 2017 May 18. pii: S0090-8258(17)30855.
    PubMed     Abstract available


  584. LUTGENDORF SK, Shinn E, Carter J, Leighton S, et al
    Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.
    Gynecol Oncol. 2017 May 17. pii: S0090-8258(17)30846.
    PubMed     Abstract available


  585. ERIKSSON AGZ, Graul A, Yu MC, Halko A, et al
    Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.
    Gynecol Oncol. 2017 May 17. pii: S0090-8258(17)30875.
    PubMed     Abstract available


  586. BARBER EL, Doll KM, Gehrig PA
    Hospital readmission after ovarian cancer surgery: Are we measuring surgical quality?
    Gynecol Oncol. 2017 May 15. pii: S0090-8258(17)30851.
    PubMed     Abstract available


  587. EDMONDSON RJ, Crosbie EJ, Nickkho-Amiry M, Kaufmann A, et al
    Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
    Gynecol Oncol. 2017 May 13. pii: S0090-8258(17)30853.
    PubMed     Abstract available


  588. COHEN JG, Prendergast E, Geddings JE, Walts AE, et al
    Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer.
    Gynecol Oncol. 2017 May 10. pii: S0090-8258(17)30802.
    PubMed     Abstract available


  589. GARCIA C, Yao A, Camacho F, Balkrishnan R, et al
    A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer.
    Gynecol Oncol. 2017 May 9. pii: S0090-8258(17)30847.
    PubMed     Abstract available


  590. TANENBAUM LM, Mantzavinou A, Subramanyam KS, Del Carmen MG, et al
    Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter.
    Gynecol Oncol. 2017 May 9. pii: S0090-8258(17)30795.
    PubMed     Abstract available


  591. ENG KH, Morrell K, Starbuck K, Spring-Robinson C, et al
    Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer.
    Gynecol Oncol. 2017 May 8. pii: S0090-8258(17)30844.
    PubMed     Abstract available


  592. DE DONATO M, Petrillo M, Martinelli E, Filippetti F, et al
    Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer.
    Gynecol Oncol. 2017 May 8. pii: S0090-8258(17)30806.
    PubMed     Abstract available


  593. GRABOSCH S, Tseng G, Edwards RP, Lankes HA, et al
    Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
    Gynecol Oncol. 2017 May 5. pii: S0090-8258(17)30787.
    PubMed     Abstract available


  594. MENDERES G, Bonazzoli E, Bellone S, Black J, et al
    SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
    Gynecol Oncol. 2017 May 1. pii: S0090-8258(17)30804.
    PubMed     Abstract available


    April 2017
  595. COLON-OTERO G, Weroha SJ, Foster NR, Haluska P, et al
    Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.
    Gynecol Oncol. 2017 Apr 28. pii: S0090-8258(17)30801.
    PubMed     Abstract available


  596. VENERIS JT, Darcy KM, Mhawech-Fauceglia P, Tian C, et al
    High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.
    Gynecol Oncol. 2017 Apr 26. pii: S0090-8258(17)30793.
    PubMed     Abstract available


  597. BOOKMAN MA, Tyczynski JE, Espirito JL, Wilson TW, et al
    Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
    Gynecol Oncol. 2017 Apr 26. pii: S0090-8258(17)30792.
    PubMed     Abstract available


  598. PETERS ML, Garber JE, Tung N
    Managing hereditary breast cancer risk in women with and without ovarian cancer.
    Gynecol Oncol. 2017 Apr 25. pii: S0090-8258(17)30794.
    PubMed     Abstract available


  599. KATCHMAN BA, Chowell D, Wallstrom G, Vitonis AF, et al
    Autoantibody biomarkers for the detection of serous ovarian cancer.
    Gynecol Oncol. 2017 Apr 17. pii: S0090-8258(17)30775.
    PubMed     Abstract available


  600. PHILLIPS A, Balega J, Nevin J, Singh K, et al
    Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer.
    Gynecol Oncol. 2017 Apr 12. pii: S0090-8258(17)30786.
    PubMed     Abstract available


  601. SHINN EH, Valentine A, Baum G, Carmack C, et al
    Comparison of four brief depression screening instruments in ovarian cancer patients: Diagnostic accuracy using traditional versus alternative cutpoints.
    Gynecol Oncol. 2017 Apr 8. pii: S0090-8258(17)30240.
    PubMed     Abstract available


  602. SIDDIQUI MK, Tyczynski J, Pahwa A, Fernandes AW, et al
    Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer.
    Gynecol Oncol. 2017 Apr 7. pii: S0090-8258(17)30770.
    PubMed     Abstract available


  603. SZENDER JB, Papanicolau-Sengos A, Eng KH, Miliotto AJ, et al
    NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30726.
    PubMed     Abstract available


  604. GARCIA-SOTO AE, Schreiber T, Strbo N, Ganjei-Azar P, et al
    Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30765.
    PubMed    


  605. CREASMAN WT, Ali S, Mutch DG, Zaino RJ, et al
    Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30233.
    PubMed     Abstract available


  606. GRAYBILL WS, Pothuri B, Chase DM, Monk BJ, et al
    Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30724.
    PubMed    


  607. SONG T, Kim MK, Jung YW, Yun BS, et al
    Minimally invasive compared with open surgery in patients with borderline ovarian tumors.
    Gynecol Oncol. 2017 Apr 2. pii: S0090-8258(17)30235.
    PubMed     Abstract available


  608. HERZOG TJ, Cohn DE
    Dose Dense Chemotherapy for Front-line Ovarian Cancer Treatment: The Price is Right?
    Gynecol Oncol. 2017;145:1-2.
    PubMed    


    March 2017
  609. WARREN JL, Harlan LC, Trimble EL, Stevens J, et al
    Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
    Gynecol Oncol. 2017 Mar 31. pii: S0090-8258(17)30232.
    PubMed     Abstract available


  610. PARK JY, Kim DY, Suh DS, Kim JH, et al
    Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors.
    Gynecol Oncol. 2017 Mar 31. pii: S0090-8258(17)30239.
    PubMed     Abstract available


  611. BARBER EL, Dusetzina SB, Stitzenberg KB, Rossi EC, et al
    Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.
    Gynecol Oncol. 2017 Mar 30. pii: S0090-8258(17)30230.
    PubMed     Abstract available


  612. SCOTT SA, van der Zanden C, Cai E, McGahan CE, et al
    Prognostic significance of peritoneal cytology in low-intermediate risk endometrial cancer.
    Gynecol Oncol. 2017 Mar 27. pii: S0090-8258(17)30228.
    PubMed     Abstract available


  613. BREGAR A, Deshpande A, Grange C, Zi T, et al
    Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Gynecol Oncol. 2017 Mar 24. pii: S0090-8258(17)30207.
    PubMed     Abstract available


  614. JANDIAL DA, Brady WE, Howell SB, Lankes HA, et al
    A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Mar 21. pii: S0090-8258(17)30229.
    PubMed     Abstract available


  615. K AU K, Peterson N, Truesdell P, Reid-Schachter G, et al
    CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    Gynecol Oncol. 2017 Mar 16. pii: S0090-8258(17)30208.
    PubMed     Abstract available


  616. MCGEE J, Giannakeas V, Karlan B, Lubinski J, et al
    Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    Gynecol Oncol. 2017 Mar 14. pii: S0090-8258(17)30153.
    PubMed     Abstract available


  617. JESKE YW, Ali S, Byron SA, Gao F, et al
    FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Mar 14. pii: S0090-8258(17)30152.
    PubMed     Abstract available


  618. NASIOUDIS D, Kanninen TT, Holcomb K, Sisti G, et al
    Prevalence of lymph node metastasis and prognostic significance of lymphadenectomy in apparent early-stage malignant ovarian sex cord-stromal tumors.
    Gynecol Oncol. 2017 Mar 11. pii: S0090-8258(17)30205.
    PubMed     Abstract available


  619. WYSHAM WZ, Schaffer EM, Coles T, Roque DR, et al
    Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
    Gynecol Oncol. 2017 Mar 10. pii: S0090-8258(17)30160.
    PubMed     Abstract available


  620. COWAN RA, Eriksson AG, Jaber SM, Zhou Q, et al
    A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2017 Mar 9. pii: S0090-8258(17)30121.
    PubMed     Abstract available


  621. DE ROOIJ BH, Ezendam NP, Nicolaije KA, Caroline Vos M, et al
    Effects of Survivorship Care Plans on patient reported outcomes in ovarian cancer during 2-year follow-up - The ROGY care trial.
    Gynecol Oncol. 2017 Mar 7. pii: S0090-8258(17)30162.
    PubMed     Abstract available


  622. VAN BROEKHOVEN ME, de Rooij BH, Pijnenborg JM, Vos MC, et al
    Illness perceptions and changes in lifestyle following a gynecological cancer diagnosis: A longitudinal analysis.
    Gynecol Oncol. 2017 Mar 6. pii: S0090-8258(17)30157.
    PubMed     Abstract available


  623. LEE M, Kim EJ, Cho Y, Kim S, et al
    Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Mar 5. pii: S0090-8258(17)30163.
    PubMed     Abstract available


    February 2017
  624. FOX E, McCuaig J, Demsky R, Shuman C, et al
    Corrigendum to "The sooner the better: Genetic testing following ovarian cancer diagnosis" [Gynecol. Oncol. 137 (2015) 423-429].
    Gynecol Oncol. 2017 Feb 27. pii: S0090-8258(17)30142.
    PubMed    


  625. CHASE DM, Chaplin DJ, Monk BJ
    The development and use of vascular targeted therapy in ovarian cancer.
    Gynecol Oncol. 2017 Feb 23. pii: S0090-8258(17)30075.
    PubMed     Abstract available


  626. SAED GM, Diamond MP, Fletcher NM
    Updates of the role of oxidative stress in the pathogenesis of ovarian cancer.
    Gynecol Oncol. 2017 Feb 23. pii: S0090-8258(17)30154.
    PubMed     Abstract available


  627. KOMIYAMA S, Manrai M, Takahashi R, Takeya C, et al
    Safe dissection of high paraaortic lymph nodes superior to the renal vein in ovarian, primary peritoneal, or fallopian tube cancer by the "Komiyama's maneuver", a modification of Kocher's maneuver.
    Gynecol Oncol. 2017 Feb 22. pii: S0090-8258(17)30126.
    PubMed     Abstract available


  628. FELICES M, Chu S, Kodal B, Bendzick L, et al
    IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
    Gynecol Oncol. 2017 Feb 21. pii: S0090-8258(17)30149.
    PubMed     Abstract available


  629. BUTTARELLI M, Mascilini F, Zannoni GF, Ciucci A, et al
    Hormone receptor expression profile of low-grade serous ovarian cancers.
    Gynecol Oncol. 2017 Feb 20. pii: S0090-8258(17)30150.
    PubMed     Abstract available


  630. SIOULAS VD, Schiavone MB, Kadouri D, Zivanovic O, et al
    Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
    Gynecol Oncol. 2017 Feb 18. pii: S0090-8258(17)30144.
    PubMed     Abstract available


  631. ROSS J, Braswell KV, da Silva LM, Mujica F, et al
    Unraveling the etiology of ovarian cancer racial disparity in the deep south: Is it nature or nurture?
    Gynecol Oncol. 2017 Feb 16. pii: S0090-8258(17)30146.
    PubMed     Abstract available


  632. MATSUO K, Machida H, Takiuchi T, Garcia-Sayre J, et al
    Prognosis of women with apparent stage I endometrial cancer who had supracervical hysterectomy.
    Gynecol Oncol. 2017 Feb 16. pii: S0090-8258(17)30115.
    PubMed     Abstract available


  633. BURGHAUS S, Fasching PA, Haberle L, Rubner M, et al
    Genetic risk factors for ovarian cancer and their role for endometriosis risk.
    Gynecol Oncol. 2017 Feb 14. pii: S0090-8258(17)30143.
    PubMed     Abstract available


  634. KOHLER RS, Kettelhack H, Knipprath-Meszaros AM, Fedier A, et al
    MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
    Gynecol Oncol. 2017 Feb 14. pii: S0090-8258(17)30128.
    PubMed     Abstract available


  635. SUIDAN RS, Ramirez PT, Sarasohn DM, Teitcher JB, et al
    A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2017 Feb 13. pii: S0090-8258(17)30132.
    PubMed     Abstract available


  636. SKALLEBERG J, Solheim O, Fossa SD, Smastuen MC, et al
    Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
    Gynecol Oncol. 2017 Feb 12. pii: S0090-8258(17)30117.
    PubMed     Abstract available


  637. CARVAJAL-HAUSDORF DE, Schalper KA, Bai Y, Black J, et al
    Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
    Gynecol Oncol. 2017 Feb 11. pii: S0090-8258(17)30079.
    PubMed     Abstract available


  638. SEAGLE BL, Shahabi S
    Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
    Gynecol Oncol. 2017 Feb 10. pii: S0090-8258(17)30125.
    PubMed     Abstract available


  639. MAI PL, Piedmonte M, Han PK, Moser RP, et al
    Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Feb 10. pii: S0090-8258(17)30119.
    PubMed     Abstract available


  640. LEFRINGHOUSE JR, Elder JW, Baldwin LA, Miller RW, et al
    Prospective validation of an intraoperative algorithm to guide surgical staging in early endometrial cancer.
    Gynecol Oncol. 2017 Feb 9. pii: S0090-8258(17)30076.
    PubMed     Abstract available


  641. KENTWELL M, Dow E, Antill Y, Wrede CD, et al
    Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
    Gynecol Oncol. 2017 Feb 3. pii: S0090-8258(17)30074.
    PubMed     Abstract available


  642. SMITH JA, Mathew L, Burney M, Nyshadham P, et al
    Corrigendum to 'Equivalency challenge: evaluation of Lipodox(R) as the generic equivalent for Doxil(R) in a human ovarian cancer orthotropic mouse model' [Gynecol. Oncol. 141 (2016) 357-363].
    Gynecol Oncol. 2017;144:448.
    PubMed    


  643. WESTIN SN, Coleman RL
    Individualized Medicine in Ovarian Cancer: Are We There Yet?
    Gynecol Oncol. 2017;144:229-231.
    PubMed    


  644. COHN DE, Backes FJ, Wallbillich JJ, Bixel K, et al
    Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine.
    Gynecol Oncol. 2017 Feb 1. pii: S0090-8258(17)30067.
    PubMed     Abstract available


  645. EOH KJ, Park JS, Park HS, Lee ST, et al
    BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
    Gynecol Oncol. 2017 Feb 1. pii: S0090-8258(17)30070.
    PubMed     Abstract available


  646. BREGAR AJ, Alejandro Rauh-Hain J, Spencer R, Clemmer JT, et al
    Disparities in receipt of care for high-grade endometrial cancer: A National Cancer Data Base analysis.
    Gynecol Oncol. 2017 Feb 1. pii: S0090-8258(17)30068.
    PubMed     Abstract available


  647. DANIELE G, Lorusso D, Scambia G, Cecere SC, et al
    Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
    Gynecol Oncol. 2017;144:256-259.
    PubMed     Abstract available


    January 2017
  648. WALLACE S, Kumar A, Mc Gree M, Weaver A, et al
    Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.
    Gynecol Oncol. 2017 Jan 31. pii: S0090-8258(17)30073.
    PubMed     Abstract available


  649. CHANAKIRA A, Westmark PR, Ong IM, Sheehan JP, et al
    Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.
    Gynecol Oncol. 2017 Jan 29. pii: S0090-8258(17)30066.
    PubMed     Abstract available


  650. DALTON HJ, Fleming ND, Sun CC, Bhosale P, et al
    Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
    Gynecol Oncol. 2017 Jan 27. pii: S0090-8258(17)30071.
    PubMed     Abstract available


  651. MATSUO K, Machida H, Takiuchi T, Grubbs BH, et al
    Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors.
    Gynecol Oncol. 2017 Jan 26. pii: S0090-8258(17)30063.
    PubMed     Abstract available


  652. ALETTI GD, Garbi A, Messori P, Achilarre MT, et al
    Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit.
    Gynecol Oncol. 2017 Jan 20. pii: S0090-8258(17)30061.
    PubMed     Abstract available


  653. WINTERHOFF BJ, Maile M, Mitra AK, Sebe A, et al
    Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells.
    Gynecol Oncol. 2017 Jan 19. pii: S0090-8258(17)30059.
    PubMed     Abstract available


  654. REISS KA, Herman JM, Armstrong D, Zahurak M, et al
    A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian
    Gynecol Oncol. 2017 Jan 18. pii: S0090-8258(17)30060.
    PubMed     Abstract available


  655. RASMUSSEN EL, Hannibal CG, Dehlendorff C, Baandrup L, et al
    Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.
    Gynecol Oncol. 2017 Jan 17. pii: S0090-8258(17)30039.
    PubMed     Abstract available


  656. HALTIA UM, Andersson N, Yadav B, Farkkila A, et al
    Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.
    Gynecol Oncol. 2017 Jan 16. pii: S0090-8258(16)31681.
    PubMed     Abstract available


  657. LIAO JB, Swensen RE, Ovenell KJ, Hitchcock-Bernhardt KM, et al
    Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer.
    Gynecol Oncol. 2017 Jan 12. pii: S0090-8258(17)30046.
    PubMed     Abstract available


  658. VON GRUENIGEN VE, Huang HQ, Beumer JH, Lankes HA, et al
    Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Jan 12. pii: S0090-8258(16)31602.
    PubMed     Abstract available


  659. GILLEN J, Gunderson C, Greenwade M, Rowland M, et al
    Contribution of age to clinical trial enrollment and tolerance with ovarian cancer.
    Gynecol Oncol. 2017 Jan 10. pii: S0090-8258(16)31687.
    PubMed     Abstract available


  660. ISLAM MM, Banerjee T, Packard CZ, Kotian S, et al
    HDAC10 as a potential therapeutic target in ovarian cancer.
    Gynecol Oncol. 2017 Jan 7. pii: S0090-8258(17)30047.
    PubMed     Abstract available


  661. TOZZI R, Hardern K, Gubbala K, Garruto Campanile R, et al
    En-bloc resection of the pelvis (EnBRP) in patients with stage IIIC-IV ovarian cancer: A 10 steps standardised technique. Surgical and survival outcomes of primary vs. interval surgery.
    Gynecol Oncol. 2017 Jan 7. pii: S0090-8258(16)31683.
    PubMed     Abstract available


  662. TUOMI T, Pasanen A, Leminen A, Butzow R, et al
    Prediction of lymphatic dissemination in endometrioid endometrial cancer: Comparison of three risk-stratification models in a single-institution cohort.
    Gynecol Oncol. 2017 Jan 6. pii: S0090-8258(17)30041.
    PubMed     Abstract available


  663. RYAN NA, Evans DG, Green K, Crosbie EJ, et al
    Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.
    Gynecol Oncol. 2017 Jan 5. pii: S0090-8258(17)30042.
    PubMed     Abstract available


  664. GOTTLIEB CE, Mills AM, Cross JV, Ring KL, et al
    Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors.
    Gynecol Oncol. 2017 Jan 5. pii: S0090-8258(16)31685.
    PubMed     Abstract available


  665. DIZON DS
    Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection.
    Gynecol Oncol. 2017 Jan 3. pii: S0090-8258(16)31684.
    PubMed    


  666. SPREAFICO A, Oza AM, Clarke BA, Mackay HJ, et al
    Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
    Gynecol Oncol. 2017 Jan 3. pii: S0090-8258(16)31620.
    PubMed     Abstract available


  667. BERGAMINI A, Pisano C, Di Napoli M, Arenare L, et al
    Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
    Gynecol Oncol. 2017;144:72-76.
    PubMed     Abstract available


    December 2016
  668. KESSOUS R, Laskov I, Abitbol J, Bitharas J, et al
    Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2016 Dec 29. pii: S0090-8258(16)31679.
    PubMed     Abstract available


  669. PIULATS JM, Guerra E, Gil-Martin M, Roman-Canal B, et al
    Molecular approaches for classifying endometrial carcinoma.
    Gynecol Oncol. 2016 Dec 28. pii: S0090-8258(16)31680.
    PubMed     Abstract available


  670. NAROD S, Sopik V
    Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?
    Gynecol Oncol. 2016 Dec 22. pii: S0090-8258(16)31615.
    PubMed    


  671. DOLL KM, Pinheiro LC, Reeve BB
    Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study.
    Gynecol Oncol. 2016 Dec 14. pii: S0090-8258(16)31623.
    PubMed     Abstract available


  672. RUBERG JL, Helm CW, Felleman BI, Helm JE, et al
    Is attendance at an ovarian cancer screening clinic a worry-reducing event? Findings from pre- to post-screening.
    Gynecol Oncol. 2016 Dec 13. pii: S0090-8258(16)31616.
    PubMed     Abstract available


  673. PRENDERGAST EN, Holzapfel M, Mueller JJ, Leitao MM Jr, et al
    Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.
    Gynecol Oncol. 2016 Dec 12. pii: S0090-8258(16)31622.
    PubMed     Abstract available


  674. MARU Y, Tanaka N, Ohira M, Itami M, et al
    Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.
    Gynecol Oncol. 2016 Dec 8. pii: S0090-8258(16)31614.
    PubMed     Abstract available


  675. RZEPECKA IK, Szafron LM, Stys A, Felisiak-Golabek A, et al
    Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
    Gynecol Oncol. 2016 Dec 7. pii: S0090-8258(16)31597.
    PubMed     Abstract available


  676. MATZ M, Coleman MP, Sant M, Chirlaque MD, et al
    The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2).
    Gynecol Oncol. 2016 Dec 5. pii: S0090-8258(16)31497.
    PubMed     Abstract available


  677. MUSA F, Pothuri B, Blank SV, Ling HT, et al
    Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
    Gynecol Oncol. 2016 Dec 5. pii: S0090-8258(16)31612.
    PubMed     Abstract available


  678. MATZ M, Coleman MP, Carreira H, Salmeron D, et al
    Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2).
    Gynecol Oncol. 2016 Dec 2. pii: S0090-8258(16)31575.
    PubMed     Abstract available


  679. GILL SE, McGree ME, Weaver AL, Cliby WA, et al
    Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gynecol Oncol. 2016 Dec 1. pii: S0090-8258(16)31577.
    PubMed     Abstract available


    November 2016
  680. SEAGLE BL, Butler SK, Strohl AE, Nieves-Neira W, et al
    Chemotherapy delay after primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2016 Nov 28. pii: S0090-8258(16)31578.
    PubMed     Abstract available


  681. NASIOUDIS D, Chapman-Davis E, Witkin SS, Holcomb K, et al
    Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma.
    Gynecol Oncol. 2016 Nov 28. pii: S0090-8258(16)31607.
    PubMed     Abstract available


  682. KARNEZIS AN, Cho KR
    Of mice and women - Non-ovarian origins of "ovarian" cancer.
    Gynecol Oncol. 2016 Nov 24. pii: S0090-8258(16)31608.
    PubMed    


  683. DE DECKER K, Speth S, Ter Brugge HG, Bart J, et al
    Staging procedures in patients with mucinous borderline tumors of the ovary do not reveal peritoneal or omental disease.
    Gynecol Oncol. 2016 Nov 23. pii: S0090-8258(16)31604.
    PubMed     Abstract available


  684. CHENG A, Li M, Kanis MJ, Xu Y, et al
    Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis.
    Gynecol Oncol. 2016 Nov 23. pii: S0090-8258(16)31518.
    PubMed     Abstract available


  685. SORIO R, Roemer-Becuwe C, Hilpert F, Gibbs E, et al
    Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
    Gynecol Oncol. 2016 Nov 18. pii: S0090-8258(16)31562.
    PubMed     Abstract available


  686. HALTIA UM, Hallamaa M, Tapper J, Hynninen J, et al
    Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors.
    Gynecol Oncol. 2016 Nov 18. pii: S0090-8258(16)31574.
    PubMed     Abstract available


  687. HEITZ F, Hengsbach A, Harter P, Traut A, et al
    Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2016 Nov 16. pii: S0090-8258(16)31567.
    PubMed     Abstract available


  688. DEL CARMEN MG, Rice LW
    International Gynecologic Cancer Society (IGCS) 2016: Meeting report.
    Gynecol Oncol. 2016 Nov 12. pii: S0090-8258(16)31572.
    PubMed    


  689. CORDEIRO VIDAL G, Babin G, Querleu D, Guyon F, et al
    Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31507.
    PubMed     Abstract available


  690. LI Y, Zhang HL, Kang S, Zhou RM, et al
    The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients' outcomes.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31566.
    PubMed     Abstract available


  691. HANNIBAL CG, Vang R, Junge J, Frederiksen K, et al
    A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31563.
    PubMed     Abstract available


  692. MARCHETTI C, Kristeleit R, McCormack M, Mould T, et al
    Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.
    Gynecol Oncol. 2016 Nov 5. pii: S0090-8258(16)31520.
    PubMed     Abstract available


  693. DAHM-KAHLER P, Borgfeldt C, Holmberg E, Staf C, et al
    Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).
    Gynecol Oncol. 2016 Nov 3. pii: S0090-8258(16)31516.
    PubMed     Abstract available


    October 2016
  694. DESALE MG, Tanner EJ 3rd, Sinno AK, Angarita AA, et al
    Perioperative fluid status and surgical outcomes in patients undergoing cytoreductive surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2016 Oct 28. pii: S0090-8258(16)31501.
    PubMed     Abstract available


  695. HAGEN B, Valla M, Aune G, Ravlo M, et al
    Indocyanine green fluorescence imaging of lymph nodes during robotic-assisted laparoscopic operation for endometrial cancer. A prospective validation study using a sentinel lymph node surgical algorithm.
    Gynecol Oncol. 2016 Oct 21. pii: S0090-8258(16)31506.
    PubMed     Abstract available


  696. CHAN JK, Java JJ, Fuh K, Monk BJ, et al
    The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG oncology/gynecologic oncology group trials.
    Gynecol Oncol. 2016 Oct 19. pii: S0090-8258(16)31421.
    PubMed     Abstract available


  697. LEE JY, Kim K, Lee YS, Kim HY, et al
    Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy.
    Gynecol Oncol. 2016 Oct 19. pii: S0090-8258(16)31498.
    PubMed     Abstract available


  698. GUELI ALLETTI S, Petrillo M, Vizzielli G, Bottoni C, et al
    Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study.
    Gynecol Oncol. 2016 Oct 18. pii: S0090-8258(16)31491.
    PubMed     Abstract available


  699. SEAGLE BL, Dayno M, Strohl AE, Graves S, et al
    Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study.
    Gynecol Oncol. 2016 Oct 16. pii: S0090-8258(16)31495.
    PubMed     Abstract available


  700. CRAIG ER, Londono AI, Norian LA, Arend RC, et al
    Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review.
    Gynecol Oncol. 2016 Oct 14. pii: S0090-8258(16)31477.
    PubMed     Abstract available


  701. KIM HS, Bristow RE, Chang SJ
    Total parietal peritonectomy with en bloc pelvic resection for advanced ovarian cancer with peritoneal carcinomatosis.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31488.
    PubMed     Abstract available


  702. LEBLANC E, Narducci F, Bresson L, Hudry D, et al
    Fluorescence-assisted sentinel (SND) and pelvic node dissections by single-port transvaginal laparoscopic surgery, for the management of an endometrial carcinoma (EC) in an elderly obese patient.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31482.
    PubMed     Abstract available


  703. BAI H, Cao D, Yuan F, Sha G, et al
    Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31481.
    PubMed     Abstract available


  704. SOLIMAN PT, Zhang Q, Broaddus RR, Westin SN, et al
    Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31483.
    PubMed     Abstract available


  705. FADER AN, Java J, Tenney M, Ricci S, et al
    Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis.
    Gynecol Oncol. 2016 Oct 12. pii: S0090-8258(16)31490.
    PubMed     Abstract available


  706. BRYK S, Farkkila A, Butzow R, Leminen A, et al
    Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors.
    Gynecol Oncol. 2016 Oct 8. pii: S0090-8258(16)31473.
    PubMed     Abstract available


  707. GARCIA-SOTO AE, Java JJ, Nieves Neira W, Pearson JM, et al
    Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
    Gynecol Oncol. 2016 Oct 7. pii: S0090-8258(16)31474.
    PubMed     Abstract available


  708. LIAO Y, Deng Y, Liu J, Ye Z, et al
    MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression.
    Gynecol Oncol. 2016 Oct 7. pii: S0090-8258(16)31410.
    PubMed     Abstract available


  709. SHAFRIR AL, Rice MS, Gupta M, Terry KL, et al
    The association between reproductive and hormonal factors and ovarian cancer by estrogen-alpha and progesterone receptor status.
    Gynecol Oncol. 2016 Oct 5. pii: S0090-8258(16)31430.
    PubMed     Abstract available


  710. WRIGHT AA, Bohlke K, Armstrong DK, Bookman MA, et al
    Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
    Gynecol Oncol. 2016;143:3-15.
    PubMed     Abstract available


    September 2016
  711. MISHKIN G, Minasian LM, Kohn EC, Noone AM, et al
    The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies.
    Gynecol Oncol. 2016 Sep 30. pii: S0090-8258(16)31432.
    PubMed     Abstract available


  712. AL-NIAIMI A, Dickson EL, Albertin C, Karnowski J, et al
    The impact of perioperative beta blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
    Gynecol Oncol. 2016 Sep 29. pii: S0090-8258(16)31425.
    PubMed     Abstract available


  713. MUELLER JJ, Kelly A, Zhou Q, Iasonos A, et al
    Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
    Gynecol Oncol. 2016 Sep 28. pii: S0090-8258(16)31420.
    PubMed     Abstract available


  714. ROSE PG, Java JJ, Morgan MA, Alvarez-Secord A, et al
    Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2016 Sep 27. pii: S0090-8258(16)31368.
    PubMed     Abstract available


  715. OH J, Barve M, Matthews CM, Koon EC, et al
    Phase II study of Vigil(R) DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
    Gynecol Oncol. 2016 Sep 24. pii: S0090-8258(16)31424.
    PubMed     Abstract available


  716. FU Y, Biglia N, Wang Z, Shen Y, et al
    Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer.
    Gynecol Oncol. 2016 Sep 23. pii: S0090-8258(16)31427.
    PubMed     Abstract available


  717. WILBUR MB, Mannschreck DB, Angarita AM, Matsuno RK, et al
    Unplanned 30-day hospital readmission as a quality measure in gynecologic oncology.
    Gynecol Oncol. 2016 Sep 21. pii: S0090-8258(16)31426.
    PubMed     Abstract available


  718. CAMPBELL G, Hagan T, Gilbertson-White S, Houze M, et al
    Cancer and treatment-related symptoms are associated with mobility disability in women with ovarian cancer: A cross-sectional study.
    Gynecol Oncol. 2016 Sep 18. pii: S0090-8258(16)31414.
    PubMed     Abstract available


  719. KATO K, Nomura H, Nagashima M, Takeshima N, et al
    Secondary debulking surgery for isolated pelvic nodal recurrence requiring external iliac vein excision and reconstruction in a patient with ovarian cancer.
    Gynecol Oncol. 2016 Sep 11. pii: S0090-8258(16)31411.
    PubMed     Abstract available


  720. HOGEN L, Thomas G, Bernardini M, Bassiouny D, et al
    The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma.
    Gynecol Oncol. 2016 Sep 9. pii: S0090-8258(16)31369.
    PubMed     Abstract available


  721. PINSKY PF, Yu K, Kramer BS, Black A, et al
    Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.
    Gynecol Oncol. 2016 Sep 8. pii: S0090-8258(16)31361.
    PubMed     Abstract available


  722. SINGH S, Guetzko M, Resnick K
    Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2016 Sep 8. pii: S0090-8258(16)31367.
    PubMed     Abstract available


  723. ALHILLI MM, Becker MA, Weroha SJ, Flatten KS, et al
    In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
    Gynecol Oncol. 2016 Sep 7. pii: S0090-8258(16)31355.
    PubMed     Abstract available


  724. MELAMED A, Hinchcliff EM, Clemmer JT, Bregar AJ, et al
    Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States.
    Gynecol Oncol. 2016 Sep 6. pii: S0090-8258(16)31365.
    PubMed     Abstract available


  725. NAKAYAMA M, Kobayashi H, Takahara T, Nishimura Y, et al
    A comparison of overall survival with 40 and 50mg/m2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data.
    Gynecol Oncol. 2016 Sep 6. pii: S0090-8258(16)31357.
    PubMed     Abstract available


  726. MANGILI G, Ottolina J, Cormio G, Loizzi V, et al
    Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study.
    Gynecol Oncol. 2016 Sep 3. pii: S0090-8258(16)31342.
    PubMed     Abstract available


    August 2016
  727. MORSE CB, Norquist BM, Harrell MI, Agnew KJ, et al
    Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2016 Aug 27. pii: S0090-8258(16)31351.
    PubMed     Abstract available


  728. GERSHENSON DM, Frazier AL
    Conundrums in the management of malignant ovarian germ cell tumors: Toward lessening acute morbidity and late effects of treatment.
    Gynecol Oncol. 2016 Aug 25. pii: S0090-8258(16)31354.
    PubMed     Abstract available


  729. RASMUSSEN CB, Jensen A, Albieri V, Andersen KK, et al
    Increased risk of borderline ovarian tumors in women with a history of pelvic inflammatory disease: A nationwide population-based cohort study.
    Gynecol Oncol. 2016 Aug 20. pii: S0090-8258(16)31344.
    PubMed     Abstract available


  730. UPPAL S, Rice LW, Beniwal A, Spencer RJ, et al
    Trends in hospice discharge, documented inpatient palliative care services and inpatient mortality in ovarian carcinoma.
    Gynecol Oncol. 2016 Aug 16. pii: S0090-8258(16)31261.
    PubMed     Abstract available


  731. SMITH B, Neff R, Cohn DE, Backes FJ, et al
    The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role.
    Gynecol Oncol. 2016 Aug 15. pii: S0090-8258(16)31260.
    PubMed     Abstract available


  732. CHAO A, Wu RC, Jung SM, Lee YS, et al
    Implication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histology.
    Gynecol Oncol. 2016 Aug 4. pii: S0090-8258(16)30985.
    PubMed     Abstract available


    July 2016
  733. GAO B, Lindemann K, Anderson L, Fereday S, et al
    Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.
    Gynecol Oncol. 2016 Jul 18. pii: S0090-8258(16)30834.
    PubMed     Abstract available


  734. BROWN AJ, Shen MJ, Urbauer D, Taylor J, et al
    Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients.
    Gynecol Oncol. 2016 Jul 18. pii: S0090-8258(16)30879.
    PubMed     Abstract available


  735. MOGENSEN JB, Kjaer SK, Mellemkjaer L, Jensen A, et al
    Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study.
    Gynecol Oncol. 2016 Jul 15. pii: S0090-8258(16)30964.
    PubMed     Abstract available


  736. CHAN JK, Gardner AB, Chan JE, Guan A, et al
    The influence of age and other prognostic factors associated with survival of ovarian immature teratoma - A study of 1307 patients.
    Gynecol Oncol. 2016 Jul 13. pii: S0090-8258(16)30835.
    PubMed     Abstract available


  737. WATSON CH, Ulm M, Blackburn P, Smiley L, et al
    Video-assisted genetic counseling in patients with ovarian, fallopian and peritoneal carcinoma.
    Gynecol Oncol. 2016 Jul 11. pii: S0090-8258(16)30963.
    PubMed     Abstract available


  738. DE LA MOTTE ROUGE T, Pautier P, Genestie C, Rey A, et al
    Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.
    Gynecol Oncol. 2016 Jul 8. pii: S0090-8258(16)30862.
    PubMed     Abstract available


    June 2016
  739. SZUBERT S, Wojtowicz A, Moszynski R, Zywica P, et al
    External validation of the IOTA ADNEX model performed by two independent gynecologic centers.
    Gynecol Oncol. 2016 Jun 30. pii: S0090-8258(16)30831.
    PubMed     Abstract available


  740. ATASEVEN B, Chiva LM, Harter P, Gonzalez-Martin A, et al
    FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited.
    Gynecol Oncol. 2016 Jun 19. pii: S0090-8258(16)30824.
    PubMed     Abstract available


  741. RAUH-HAIN JA, Birrer M, Del Carmen MG
    "Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities".
    Gynecol Oncol. 2016 Jun 16. pii: S0090-8258(16)30771.
    PubMed     Abstract available


  742. ROQUE DR, Makowski L, Chen TH, Rashid N, et al
    Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project.
    Gynecol Oncol. 2016 Jun 8. pii: S0090-8258(16)30811.
    PubMed     Abstract available


  743. ESSELEN KM, Terry KL, Samuel A, Elias KM, et al
    Endosalpingiosis: More than just an incidental finding at the time of gynecologic surgery?
    Gynecol Oncol. 2016 Jun 2. pii: S0090-8258(16)30765.
    PubMed     Abstract available


  744. WRIGHT JD, Chen L, Jorge S, Burke WM, et al
    Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery.
    Gynecol Oncol. 2016;141:531-7.
    PubMed     Abstract available


    May 2016
  745. LIAO JB
    Immunotherapy for Gynecologic Cancers: State of the Science.
    Gynecol Oncol. 2016 May 27. pii: S0090-8258(16)30758.
    PubMed    


  746. JORGE S, Jones NL, Chen L, Hou JY, et al
    Characteristics, treatment and outcomes of women with immature ovarian Teratoma, 1998-2012.
    Gynecol Oncol. 2016 May 21. pii: S0090-8258(16)30753.
    PubMed     Abstract available


  747. DAI D, Thiel KW, Salinas EA, Goodheart MJ, et al
    Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations.
    Gynecol Oncol. 2016 May 16. pii: S0090-8258(16)30731.
    PubMed     Abstract available


  748. SCHLAPPE BA, Mueller JJ, Zivanovic O, Gardner GJ, et al
    Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
    Gynecol Oncol. 2016 May 14. pii: S0090-8258(16)30734.
    PubMed     Abstract available


  749. KARLSEN NM, Karlsen MA, Hogdall E, Nedergaard L, et al
    Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT).
    Gynecol Oncol. 2016 May 7. pii: S0090-8258(16)30684.
    PubMed     Abstract available


  750. XIONG J, He M, Hansen K, Jackson CL, et al
    The clinical significance of K-ras mutation in endometrial "surface epithelial changes" and their associated endometrial adenocarcinoma.
    Gynecol Oncol. 2016 May 3. pii: S0090-8258(16)30679.
    PubMed     Abstract available


  751. HOLLESTELLE A, van der Baan FH, Berchuck A, Johnatty SE, et al
    No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
    Gynecol Oncol. 2016;141:386-401.
    PubMed     Abstract available


    April 2016
  752. STROHL AE, Feinglass JM, Shahabi S, Simon MA, et al
    Surgical wait time: A new health indicator in women with endometrial cancer.
    Gynecol Oncol. 2016 Apr 22. pii: S0090-8258(16)30146.
    PubMed     Abstract available


  753. KOBEL M, Atenafu EG, Rambau PF, Ferguson SE, et al
    Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
    Gynecol Oncol. 2016 Apr 9. pii: S0090-8258(16)30109.
    PubMed     Abstract available


    March 2016
  754. KIM TH, Kim HS, Kim TJ, Chang SJ, et al
    Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis.
    Gynecol Oncol. 2016 Mar 25. pii: S0090-8258(16)30087.
    PubMed     Abstract available


  755. GHEZZI F, Cromi A, Fanfani F, Malzoni M, et al
    Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: a multi-institutional experience.
    Gynecol Oncol. 2016 Mar 24. pii: S0090-8258(16)30086.
    PubMed     Abstract available


  756. WITKOWSKI L, Goudie C, Ramos P, Boshari T, et al
    The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.
    Gynecol Oncol. 2016 Mar 11. pii: S0090-8258(16)30071.
    PubMed     Abstract available


  757. DAO F, Schlappe BA, Tseng J, Lester J, et al
    Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2016 Mar 11. pii: S0090-8258(16)30067.
    PubMed     Abstract available


  758. BACKES FJ, Walker CJ, Goodfellow PJ, Hade EM, et al
    Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer.
    Gynecol Oncol. 2016 Mar 5. pii: S0090-8258(16)30062.
    PubMed     Abstract available


  759. DELGADO E, Boisen MM, Laskey R, Chen R, et al
    High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome.
    Gynecol Oncol. 2016 Mar 2. pii: S0090-8258(16)30054.
    PubMed     Abstract available


    February 2016
  760. COX BAUER CM, Greer DM, Kram JJ, Kamelle SA, et al
    Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer.
    Gynecol Oncol. 2016 Feb 25. pii: S0090-8258(16)30041.
    PubMed     Abstract available


  761. SIMONE CG, Markham MJ, Dizon DS
    Chemotherapy in ovarian germ cell tumors: A systematic review.
    Gynecol Oncol. 2016 Feb 9. pii: S0090-8258(16)30033.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: